Ref. No.: F.02(258)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-05/2019/113 Dated :25.01.2019

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: rmsc@nic.in,
edprocurement@gmail.com

E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Ending on 31.03.2021)

!! सर्वे सन्तु निरामयाः!!

LAST DATE OF SUBMISSION OF ONLINE BIDS	**25.02.2019 & 6.00 PM**
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	**26.02.2019 & 11.00 AM**

Ministry of Health & Family Welfare
Government of Rajasthan
RMSCL
"Mukhyamantri Nishulak DavaYojana"
'D' Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: rmsc@nic.in

Ref. No.: F.02(258)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-05/2019/113 Dated :25.01.2019

Notice Inviting E-Bids

E-bids are invited up to 6.00 PM of 25.02.2019 from approved Drugs Testing Laboratories situated in India for analysis of Drugs. (Ending on **31.03.2021**) Details may be seen in the Bidding Documents at our office or at the website of State Public procurement Portal http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in. , www.rmsc.nic.in and may be downloaded from there.

Note:- If any amendment is carried out in the tender specifications and terms & conditions following pre-bid meeting, the same will be uploaded on the Departmental website www.rmsc.nic.in, sppp.raj.nic.in and https:// eproc.rajasthan.gov.in. In case any inconvenience is felt, please contact on telephone number i.e. 0141- 2228064

(UBN :- MSC1819SLRC00097)

Executive Director (Procurement)
RMSCL

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Ending on 31.03.2021)

Bid Reference	**:**	F.02(258) / RMSCL / ED (P) EMPANELMENT / DTL / NIB-05 / 2019 /113 Dated :-25.01.2019
Pre- bid conference	**:**	**05.02.2019 at 11.00 A.M.** (RMSC meeting Hall)
Date and time for downloading bid document	**:**	**31.01.2019 from 2.00 PM**
Last date and time of submission of online bids	**:**	**25.02.2019 at 6.00 PM**
Date and time of opening of Online technical bids	**:**	**26.02.2019 at 11.00 PM**
Cost of the Bid Document	**:**	**Rs. 2000/-**
RISL Processing Fees	**:**	**Rs. 1000/-**
EMD	**:**	**Rs. 20000/-**

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
RAJASTHAN

E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Ending on 31.03.2021)

"CONFIDENTIALITY IS THE ESSENCE OF THIS BID"

1. LAST DATE FOR RECEIPT OF BIDS, BID FEES, EMD, RISL PROCESSING FEES AND EMPANELMENT FEES

a) E-Bids [In Two Separate Bids (Technical Bid & Price Bid)] Will Be Received Till 06.00 PM on 25.02.2019 By The Rajasthan Medical Services Corporation Ltd, For The Empanelment Of Analytical Testing Laboratories For The Test And Analysis Of DRUGS (Ending on 31.03.2021) in English language. Proposal received after the closing date and time shall not be considered.

b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Earnest Money deposit. No refund of tender fee is claimable under any circumstances to any of the bidder.

c) The e-Bids will be received on web-portal of e-procurement of GoR. Every Bidder will be required to pay the Bid form fee Rs. 2000.00 for downloaded from the website, EMD as applicable in Bid condition no. **6** and processing fee of Rs.1000.00 of R.I.S.L. through three separate prescribed challans (***format enclosed in Annexure- I)*** in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 25.02.2019 or through D.D. / bankers cheque in favour of M.D. RMSCL (tender fees and EMD), MD, RISL (tender procession fees) physically in the office of RMSCL by 6.00 PM on 25.02.2019 The bidders shall submit/upload scanned copy of all the challans in Technical Bid**.** Bids will be opened only after ensuring receipt of Bid fees along with processing fees and EMD. **In the absence of Bid fees, processing fees and EMD the Bids will be rejected and will not be opened.**

2. <u>Eligibility Criteria for Empanelment :-</u>

(1) Drug Testing Laboratories should have valid Approval for carrying out test on drugs under the Drugs and Cosmetics Act, 1940 and Rules there under. Three years standing in the test & analysis of **drugs/chemicals or food** items and the lab shall be entitled for empanelment for the categories of items for which lab is having approval. Bid is invited from approved Drugs Testing Laboratories situated in India.

(2) The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules there under and should hold schedule L-1 certificate or should have approval from Drug Control Department <u>and</u> NABL accreditation with proper scope of accreditation to undertake testing of drugs, surgical and sutures. GLP certificate should be clear, it should not contain ambiguous expressions, like 'by and large'.

(3) The laboratory should have an average annual turnover of **not** less than **Rs. 1 Crore** for past preceding three years (2014-15, 2015-16 and 2016-17 **or 2015-16, 2016-17 and 2017-18**).

(4) The lab should have undertaken test and analysis of drugs and supplies of similar nature of at least three government institutions/corporation/reputed manufacturers of drug formulations.

(5) The lab should not stand banned / debarred or blacklisted by any State **or** Central Government Organizations or its central procurement agencies on the due date of bid submission. If a bidder or an approved bidder will be found defaulter for concealing this fact, then following actions may be taken.

(i) Bid rejection

(ii) EMD forfeiture

(iii) Agreement rejection

(iv) S.D. forfeiture

(v) Blacklisting

(6) The laboratory and its responsible persons should not have been convicted under the provisions of applicable laws with regard to the activities and conduct of the laboratory.

(7) The laboratory should have all necessary instruments/equipments/machines for testing of drugs with minimum three functional HPLC's.

3 **TECHNICAL BID**

The Bidder must furnish the following in technical bid.

a. Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be testing at Annexure-VII). The bidder has to mentioned type of test for each item to be carried out by him, the filled up annexure VII to be submitted with technical bid.

NOTE:- Bidders have to mentioned all the test parameters compulsorily in column no.5 of annexure-VII, If any bidder does not mention any parameter/parameters as narrated in column no. 4, then the bid shall be treated as non-responsive for that particular drug item.

b. The bidders shall submit/upload scanned copy of all the challans in Technical Bid deposited for Bid fees, RISL processing fee and Earnest Money, in case deposited in any branch of PNB throughout country. The required EMD / Tender fees/ RISL fee may be in form of physical D.D./ BC along with letter. D.D. / bankers cheque shall be in favour of M.D. RMSCL (tender fees and EMD), MD, RISL (tender procession fees).

c. Attested Photocopy of Analytical approval duly renewed up to date, issued by the State Licensing Authority.

d. **Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate) and Copy of NABL accreditation with scope for testing of drug formulations.**

e. Documentary evidence of having analysed Drugs, chemicals, foods and other items for the last three years with a statement in the proforma as given in Annexure III.

f. Attested copy of certificate of registration for service tax.

g. Non- Conviction Certificate by the State Licensing Authority/ competent authority.

h. Annual turnover statement for 3 year i.e. 2014-2015, 2015-2016 and 2016-17 **or 2015-16, 2016-17 and 2017-18** certified by the practising Chartered Accountant.

i. Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2014-2015, 2015-2016 and 2016-17 **or 2015-16, 2016-17 and 2017-18** duly audited or certified by the practicing Chartered Accountant.

j. The following information in the form given in Annexure IV (a) to IV(d).

a) The list of permanent technical qualified personnel employed in the laboratory with proof of their qualifications and relevant approvals.
b) The list of sophisticated instruments available in the laboratory.
c) Micro Biological facilities available in the laboratory.

d. List of Reference Samples along with their date of procurement and quantities.

e. In the case of Non- Pharmacopoeial Products the Method of Analysis Should be appended to the Report, especially if the sample is declared as "not of standard quality".

k. A declaration in the proforma given in Annexure V duly signed and Notarized.

l. Details of Laboratory in Annexure – VI.

m. A copy of PAN issued by Income Tax Department.

n. Documentary evidence for the constitution of the company / concern.

o. At any time prior to opening of price bid RMSC either at their own initiate or in response to clarification requested by prospective tender, may modify tender by issuing an amendment. Such amendments shall be loaded on E-Proc site and will be the part of tender.

p. Bidders has to fill up the checklist enclosed at Annexure VIII indicating the infrastructure and testing facilities available in the lab.

4 PRICE BID :

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). **BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only**. **The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be quoted separately at last entry of BOQ. Any type of uncalled for clarification on prices and or rebates shall not be accepted.**

It is further clarified that if a bidder does not fill the IGST, CGST, SGST column, or does not fill any other column, than the bid shall be treated as uncompleted and liable to be rejected prima-facie.

5 OPENING OF TECHNICAL BID AND FINANCIAL BID EVALUATION

1. There after the Bidders found eligible as stated above on the basis of the examination on technical bid, the financial bid will be opened and after scrutiny thereof, including inspection of the laboratory, if required, the acceptable rates for analysis will be decided and communicated.

6 EARNEST MONEY DEPOSIT

The Earnest Money Deposit shall be Rs. 20,000/- The Earnest Money Deposit shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country up to 25.02.2019 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 6.00 PM on 25.02.2019 Earnest Money Deposit in any other form will not be accepted.

The Bids submitted without sufficient EMD will be summarily rejected. The EMD will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails within specified time to sign the contract agreement or fails to furnish the security deposit.

Government undertaking PSU are exempted for EMD deposition on producing the certificate issued by the competent authority.

7 GENERAL CONDITIONS

1. The details of the Drugs, to be analysed shall be given in **Annexure VII**.
2. The Bidder should quote the rates for complete analysis of each product and name of test to be performed, methodology to be used for each test should be mentioned in **Annexure-VII**. **However wherever rates for individual test are demanded, they should be furnished accordingly in BOQ. Wherever test are prescribed and their name and methodology for testing are not stated, such lab will not be considered responsive testing for such item.**
3. The rates quoted should be exclusive of taxes.
4. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the BID period.
5. Analytical Laboratory, which also has its manufacturing activity, if empanelled by RMSC, then Samples of its own manufacturing unit shall not be sent to its empanelled laboratory for testing.
6. The laboratory will not be permitted to outsource any test from other laboratory.

7. RMSCL shall have the right to cause the laboratory to be inspected by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.
8. Conditional tender will not be accepted and rejected immediately.

8. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
2. The Managing Director, Rajasthan Medical Services Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bided for, without assigning any reason.
3. The Managing Director, Rajasthan Medical Services Corporation Limited has the right to accept one or more bidders depending on the volume of analytical work.

9. AGREEMENT

1. **The agreement with empanelled laboratories will remain valid up to 31.03.2021. If Required period of contract can be extended upto 3 months same rate, terms and condition without any prior consent and shall be binding on approved bidder.**
2. RMSCL will issue letters of Intent (LOIs) to successful bidders and bidders who are empanelled will have to execute an agreement on a non-judicial stamp paper of value **Rs. 1000 /-** (Stamp duty to be paid by the Bidder), in favour of Managing Director, Rajasthan Medical Services Corporation Limited Jaipur within 15 days from the date of receipt of the intimation to them informing that their BIDs have been accepted. The format of agreement will be issued by RMSCL.
3. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.
4. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

10. <u>PERFORMANCE SECURITY</u>

1. The successful Bidders shall be required to pay a security deposit of **Rs. 50,000/-** ***in the form of demand draft*** at the time of execution of the

agreement. **Performance security will be refunded three month after expiry of rate contract subject to successful completion of services.**

11. COMPLETE ANALYSIS & REPORTING CONDITIONS

1. (a) On empanelment and entrustment of the job, the Analytical Laboratory should

furnish the test reports within:

i. 10 days from the receipt of the sample in case of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid Oral Preparations (non – sterile products)

ii. 21 days from the receipt of the sample in the case of I.V. Fluids and injectables and other items requiring test for sterility.

b) All the tests mentioned in IP/BP/USP/Drugs & Cosmetics Act. etc. including addendus, (as the case may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample. If any drug is not included in the pharmacopeia at the time of bid opening and letter on it is including in any pharmacopeia the drug should be tested as per pharmacopeia specification.

c) "COMPLIES" or "PASSES" in the result column of the report is treated as incomplete report, if the result has some numerical value.

d) Every test report must have remarks either as "Standard Quality" or "Not of Standard Quality". Any ambiguity/cutting in reports will not be accepted (clear mention of "standard quality or not of standard quality" should be stated in bold letters and crossing/cutting of one of these will not be accepted).

e) Reports should be in A4 size (8.27" X 11.69") paper of good quality.

f) Report should be issued on form 39 and should have S. no. , name of drug sample, code no., batch no., mfg. date, exp. date, description of tests, protocol of test specified & applied, findings & results obtained and should be signed by person-in-charge of testing. In case of Not of Standard Quality Reports the reports shall be release on Pink/Red colored paper for easy identification of NOSQ drugs.

g) Reports should be attached along with Spectra / Chromatography data sheets, if applicable and it will be considered incomplete if spectra or chromatograms are not attached.

2. All test reports of each batch of sample should be submitted to the RMSC in triplicate. In case of failure of a sample, the result should be communicated immediately to the Executive Director (Q.C.) through phone / E-mail and the report should be sent along with protocol.

3. If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, the same should be reported within 24 hours of receipt of such a sample by phone or E-mail and the sample should be returned to the Executive Director (Quality Control), Rajasthan Medical Services Corporation Limited, Jaipur after taking necessary telephonic or mail consent. In case of inability of laboratory to undertake the testing, a penalty of 25% of testing charges applicable for that product / products will be recovered.

4. If placebo or standard test procedure of any product is required the same should be demanded within 48 hours with return request. Period lapsed/taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.

5. If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the E.D. (Quality Control), Rajasthan Medical Services Corporation Limited Jaipur by Fax or E-mail.

6. The Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representative(s) has / have the right to inspect the laboratories of the Bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representatives may also inspect any empanelled laboratory, at any point of time during the continuance of the BID and terminate / cancel its empanelment or any orders issued to the laboratory, not to entrust any further testing job to the laboratory based on facts brought out during such inspections.

7. The successful lab shall have to make own arrangement for collection of sample, from RMSC Headquarters.
8. It will be sole discretion of RMSC to allot the samples to any empanelled lab in case when there are more than one lab approved for an item. (One or more Laboratories may be empanelled by this tender.)

12. PAYM ENT PROVISIONS

1. No advance payment towards any analysis will be made to the empanelled Bidder.
2. No payment will be made for the incomplete analysis or incomplete report. Deliberate omission of any critical test will be viewed seriously and shall invite action against the laboratory as deemed fit by RMSCL.
3. Payments towards the analysis of Drugs will be made as per approved rate plus tax on it will be along with Tax at the prevailing rate as applicable at the time of payment.

13. PENALTIES

1. If the successful Bidder fails to execute the agreement and payment of security deposit within the time specified or withdraws the BID after intimation of the acceptance of the BID has been sent to or owing to any other reasons, he is unable to undertake the contract, the empanelment will be cancelled and the Earnest Money Deposit deposited by the Bidder shall stand forfeited in favour of the Rajasthan Medical Services Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Rajasthan Medical Services Corporation Limited due to of breach of BID conditions. Such damages shall be assessed by the Managing Director, Rajasthan Medical Services Corporation Limited whose decision shall be final.
2. Non performance of any BID or empanelment conditions will disqualify a laboratory to participate in the BID for the period as decided by RMSCL.
3. If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Rajasthan Medical Services Corporation Limited, the Analytical Laboratory will be black listed for a period considered suitable. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director of

Drugs Control for suitable action against them under Drugs & Cosmetics Act & Rules.

4. The Managing Director, Rajasthan Medical Services Corporation Limited will be at liberty to terminate without assigning any reasons, the empanelment of any laboratory either wholly or in part at one month's notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
5. In all matters pertaining to the BID, the decision of the Managing Director, Rajasthan Medical Services Corporation Limited shall be final and binding.
6. (i)If the laboratory requires an extension in time for submission of test report, on account of occurrence of any hindrance he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of ***furnishing the test report***.

   (ii)The Executive Director (QC)/ Drug Controller/ADC (QC) may extend the testing period with or without liquidated damages in case they are satisfied that the delay in the submission of test reports is on account of any hindrances, he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of submission of report. Reasons shall be recorded.

   (iii)**Extension in testing period:-** In case of extension in the testing period with liquidated damages the recovery shall be made on the basis of following percentages of ***testing charges*** which the Bidder has failed to submit:-

   (a) Delay upto one fourth period of the prescribed testing period; 2.5%

   (b) Delay exceeding one fourth but not exceeding half of the prescribed testing period; 5%

   (c) Delay exceeding half but not exceeding three fourth of the prescribed testing period; 7.5%

   (d) Delay exceeding three fourth of the prescribed testing period; 10%

   Note: Fraction of a day in reckoning period of delay in ***furnish the test report*** shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

   iv. If, at any time during the continuance of this Agreement, the ***laboratory*** has, in the opinion of the Purchaser, delayed in submitting any test report, by the

reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause, on a specific request made by the laboratory, the time for submitting test report may be extended by the ***RMSCL*** purely at his discretion for such period as may be considered reasonable. No further representation from the ***laboratory*** will be entertained on this account.

14. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

(ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.

(iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

15. GRIEVANCE REDRESSAL DURING EMPANELMENT PROCESS:

The Designation and address of the First Appellate Authority is Special_ Secretary/ Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan.

The Designation and address of the Second Appellate Authority is Principal Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan and Chairman, RMSCL.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.

iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

(a) Determination of need of empanelment;

(b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;

(d) Cancellation of a empanelment process;

(e) Applicability of the provisions of confidentiality.

v. Form of Appeal

(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.

(b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.

(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.

(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

(i) Hear all the parties to appeal present before him; and

(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

16. <u>COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:</u>

Any person participating in a empanelment process shall-

a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;

b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;

c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;

d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;

e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;

f) Not obstruct any investigation or audit of a procurement process;

g) Disclose conflict of interest, if any; and

h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

17. Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

a. Have controlling partners/shareholders in common; or

b. Receive or have received any direct or indirect subsidy from any of them; or

c. Have the same legal representative for purposes of the Bid; or

d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or

e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or

g. Bidder or any of its affiliates has been hired (or is proposed to be hired0 by the Procuring Entity as engineer-in0chage/ consultant for the contract.

18. <u>JURISDICTION</u>

1. In the event of any legal dispute arising out of the BID such dispute would be subject to the jurisdiction of the Civil courts within the city of Jaipur only.

Managing Director
Rajasthan Medical Services Corporation

Annexure - 1

CAUTION : USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM"

Bank Copy

punjab national bank

DIST. NO.

Branch

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 2246002100024414

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹

Commission ₹ 0 0 0 0 0 - 0 0

Total amount ₹ -

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

Customer Copy

punjab national bank

DIST. NO.

Branch

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 2246002100024414

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/ Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹

Commission ₹ 0 0 0 0 0 - 0 0

Total amount ₹ -

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

ANNEXURE- II
Ref. Clause No. 2 (3), 3(h)

ANNUAL TURN OVER STATEMENT

The Annual Turnover of M/s._____ for the past three years are given below and certified that the statement is true and correct.

S.No.	Years	Turnover in Lakhs
1	2014-15	
2	2015-16	
3	2016-17	
Total		**Rs. Lakhs**
Average turnover per annual		**Rs. Lakhs**

or

S.No.	Years	Turnover in Lakhs
1	2015-16	
2	2016-17	
3	2017-18	
Total		**Rs. Lakhs**
Average turnover per annual		**Rs. Lakhs**

Date:

Seal:

Siganture of Auditor/
Chartered Accountant
(Name in Capital)

ANNEXURE III
Ref. Clause No: 3 (e)

PROFORMA FOR PERFORMANCE STATE MENT
(for a period of last 3 years)

Name of the Laboratory : _____

Address:_____

_____

_____

Types of Samples Analysed	No. of Samples Analysed during **(2014-15, 2015-16 and 2016-17)** **or** **(2015-16, 2016-17 and 2017-18)**
01. Tablets / Capsules / Pessaries/Dry Powders	
02. Injectables	
03. Liquid Preparations	
04. Ointments / Creams / Gels	
05. Others (Specify)	
06. Surgicals (Specify item names)	
07. Sutures (Specify types)	
08. Implants	
09. Devices	

Signature :
Date :
Name of the Lab :
Office Seal :

ANNEXURE – IV (a)
Ref. Clause No: 3 (j) (a)

PERSONNEL IN QC DEPARTM ENT

Name of the Technical Staff approved by State Licensing Authority along with his Designation, Highest Qualification, Experience (Experience relevant to analysis of drugs/surgical/sutures)

Signature :

Date :

Nam e of the Lab :

Office Seal :

ANNEXURE – IV (b)
Ref. Clause No: 3(j) (b)

LIST OF SOPHISTICATED EQUIPMENT/INSTRUMENT/APPARATUS AVAILABLE IN THE LAB

S.No.	Name of the Equipment Instruments / Apparatus	Make & Description	Date of Installation	Date of last Validation	Approved for testing of drugs from State licensing Authority since……..

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (C)
Ref. Clause No: 3(j) (c)

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF INSTALLATION, make and approval from State Licensing Authority to permit microbiological testing in the Lab.

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (d)
Ref. Clause No: 3(j) (d)

LISTOF REFERENCES SAMPLES ALONG WITH THEIR DATE OF PROCUREMETN AND QUANTITIES

Signature :

Name of the Lab :

Date :

Official Seal:

Affidavit

(on Non Judicial Stamp of Rs.500/-)

ANNEXURE – V
Ref. Clause No: 3(k)

DECLARATION FORM

1. I (Name of the Bidder) S/O_____, Age_____, resident of_____, am proprietor /Partner/Director having our office at_____ and the approved drug testing laboratory at_____do hereby declare that I have carefully read all the conditions of BID of Rajasthan Medical Services Corporation Ltd., Jaipur, for the BIDs floated for empanelment of approved drugs testing laboratories for analysis of drugs. (ending on 31.03.2021) and shall abide by all the conditions set forth therein.
2. I further declare that I possess valid approval for testing of all the drugs/surgicals & sutures for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
3. That the approval to test drugs/surgical & sutures have been obtained on Form 37 bearing No._____which is valid/renewed up to_____.
4. That the Bidder firm is a proprietorship/Partnership/Pvt. Ltd./ltd. firm and following are the other partners/directors:-

S.No.	Name of Partner/Director	Age	Present & Permanent Address

5. That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission.

   Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of **wrong reporting of test results** or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.

That I/We have carefully read all the conditions of bid in Ref. No.**:** F.02(258)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-05/2019/113 Dated :25.01.2019

6. For the empanelment of analytical testing laboratories for the test and analysis of DRUGS (Ending on 31.03.2021) for Rajasthan medical services corporation and accept all conditions of bid, including amendments if any.

7. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:
    a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
    b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
    c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
    d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
    e. l/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition;

8. Our complete address for communication with phone no.:- ----------
---
---

9. E mail address :- ----------

10. Bank detail for e banking :-

    Name of account holder ……

(Affidavit Page2)

    Full name of Bank with Branch ……

    A/c no. with full digits……..

    IFSC code ……..

(Deponent)

Signature :

Date :

Name of the Lab :

Office Seal :

Verification

I……..S/o……(Designation)…….

Affirm on oath that the contents/information from para 1 to 10 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid and forfeiting the earnest money deposit and or performance security, for which I shall be solely responsible and the laboratory / firm may be Debarred/Banned/ prosecuted for the same

(Name of Deponent & Signature)

ATTESTED BY NOTARY PUBLIC

ANNEXURE – VI
Ref.Clause No: 3

(l)

DETAILS OF LABORATORY

1. Name of the Laboratory & Full Address :

   Phone No (landline) :

   Fax :

   E-mail :

2. Other Branches & their Address (if any) :

3. Whether the firm has it own manufacturing unit? :

   If yes give details of address, license number etc.

4. Date of Inception :

5. Approval No. & Date :

6. Issued by :

7. Valid up to :

8. Schedule L-1 certificate its no. and date of issue (GLP) :

   or

9. (i) NABL Accreditation no. & date
   (ii) Scope of Accreditation
   (iii) Its validity.

10. Name of the authorized signatory :

11. Specimen Signature of the authorized Signatory :

12. Names & Specimen Signatures of the Approved technical Staff who are authorized to sign the test reports :

ANNEXURE –VII
Ref: Clause no. 3 (a),7(1)

NOTE:- Bidders have to mentioned all the test parameters compulsorily in column no.5 (Agree to perform test parameters), If any bidder does not mention any parameter/parameters as narrated in column no. 4, then the bid shall be treated as non-responsive for that particular drug item.

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
1	2	Bupivacaine Hydrochloride in Dextrose Injection USP Each ml contains Bupivacaine Hydrochloride 5.0 mg, Dextrose 80.0 mg.	Description	
			Identification A (TLC)	
			Identification B (by HPLC)	
			pH	
			Bacterial endotoxins	
			Volume in container	
			Particulate matter (by liquid particle counter)	
			Sterility	
			Assay:	
			Bupivacaine Hydrochloride (by HPLC)	
			Dextrose (by Optical rotation)	
2	4	Bupivacaine Injection IP 0.5%	Description	
			Identification A by IR	
			Identification B (Chemical)	
			pH	
			Related substances (by TLC)	
			2, 6-Dimethylaniline (HPLC)	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Sterility	
			Assay: (by HPLC)	
3	5	Drotaverine Hydrochloride Injection 40 mg/2 ml	Description	
			Identification of Drotaverine hydrochloride (by HPLC)	
			pH	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
4	6	Halothane BP 250 ml	Description	
			Identification A (by Chemical)	
			Identification B (by IR)	
			Identification C (Chemical)	
			Acidity and Alkanility	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Relative Density	
			Distillation range	
			Volatile Related Substances (By GC)	
			Thymol (By GC)	
			Bromide and Chlorides	
			Bromine and Chlorine	
			Non-Volatile Matter	
			Uniformity of container content	
5	7	Isoflurane USP	Description	
			Identification (by IR)	
			Chlorides	
			Limits of Fluoride	
			Non Volatile Residue	
			Organic impurities (by HPLC)	
			Refractive Index	
			Water	
			Acidity and Alkanility	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
6	8	Ketamine Injection IP 50 mg/ml	Description	
			Identification A (by UV)	
			Identification B (by UV)	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
7	9	Lignocaine Ointment 5%	**Lidocaine Ointment BP**	
			Description	
			Identification A (by IR)	
			Identification **B** (by HPLC)	
			Minimum Fill	
			Uniformity of mass	
			Microbial Examination	
			Staphylococcus species	
			Pseudomonas species	
			Assay: (by HPLC)	
8	10	Lignocaine and Adrenaline Injection IP Each ml. Contains:- Lignocaine Hydrochloride IP 20 mg. Adrenaline IP	Description	
			Identification A (Chemical)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
		0.01mg	Identification B (Chemical)	
			Identification C (Melting Point)	
			pH	
			Particulate matter	
			Extractable volume	
			Sterility	
			Assay:	
			for Lignocaine hydrochloride (Chemical)	
			for Adrenaline by (by HPLC)	
9	11	Lignocaine and Dextrose Injection IP Each ml contains Lignocaine 50 mg and Dextrose (monohydrate) 75 mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Sterility	
			Assay:	
			for Lignocaine hydrochloride (by titration)	
			for Dextrose (by Optical rotation)	
10	12	Lignocaine Gel IP 2%	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			2,6-Dimethylaniline	
			Contents of Packaged Dosage Forms	
			Assay: Lignocaine hydrochloride (by titration)	
			Sterility	
11	13	Lignocaine Injection IP 2%	Description	
			Identification A (Chemical)	
			Identification B: Melting Point	
			Identification C (Chemical)	
			pH	
			2,6-Dimethylaniline	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: Lignocaine hydrochloride (by titration)	
			Sterility	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
12	14	Propofol Injection IP/BP/USP 10 mg/ ml	Description	
			Identification A (IR)	
			Identification B: by HPLC	
			pH	
			Propofol Quinone and propofol Dimer (HPLC)	
			Globule Size	
			Free Fatty Acid	
			Lyso-lecithine (HPLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: by HPLC	
			Sterility	
13	15	Thiopentone Injection IP 0.5 gm	Description	
			Identification A (by IR)	
			Identification C: Melting Point	
			Identification E (by Chemical)	
			Appearance of solution	
			Related substances (by HPLC)	
			Average net content	
			Uniformity of weight	
			Loss on drying	
			Bacterial endotoxins	
			Clarity of solution test a and b	
			Particulate matter	
			Assay:	
			For Thiopentone (by Chemical)	
			For Sodium (by Chemical)	
			Sterility	
14	19	Diclofenac Sodium Injection IP 25 mg/ ml (IM/IV use)	Description	
			Identification (by TLC)	
			pH	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
15	20	Diclofenac Gastro Resistant Tablets IP 50 mg (Enteric Coated)	Description	
			Identification (by TLC)	
			Average weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight of Tablets	
			Disintegration time	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour (by TLC	
16	21	Fentanyl Citrate Injection IP 50 mcg /ml	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Identification C (Chemical)	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
17	22	Ibuprofen and Paracetamol Tablets IP Ibuprofen 400 mg +Paracetamol 325mg	Description	
			Identification of:	
			Ibuprofen (by HPLC)	
			Paracetamol (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Ibuprofen	
			Paracetamol	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Ibuprofen (by HPLC)	
			Paracetamol (by HPLC)	
18	23	Ibuprofen Tablets IP 200 mg (Coated)	Description	
			Identification A (by IR)	
			Identification B: Melting Point	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Dissolution (by UV)	
			Related Substances (by TLC)	
			Assay: Ibuprofen (by titration)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification of colour	
19	24	Ibuprofen Tablets IP 400 mg (Coated)	Description	
			Identification A (by IR)	
			Identification B: Melting Point	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Dissolution (by UV)	
			Related Substances (by TLC)	
			Assay: Ibuprofen (by titration)	
			Identification of colour	
20	25	Morphine Sulphate Injection IP 10mg/ml	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
21	26	Paracetamol Drops [Paediatric Paracetamol Oral Suspension IP] (Each ml contains Paracetamol 150 mg)	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Weight per ml	
			Related substances (by HPLC)	
			Uniformity of volume: Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
			Identification of colour (by TLC)	
22	27	Paracetamol Syrup IP 125 mg/5ml (40% Sugar base with strawberry flavour and carmoisine colour)	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Weight per ml	
			4-Aminophenol (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of volume: Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
			Identification of colour (by TLC)	
			Additional test	
			Sugar content (by Gravimetric)	
23	28	Paracetamol Tablets IP 500 mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay (by UV)	
24	29	Paracetamol Injection 150mg/ml	Description	
			Identification of paracetamol (by HPLC)	
			pH	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
25	30	Pentazocine Injection IP 30mg/ml (IM/IV Use)	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			pH	
			Related substances (by TLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
26	32	Tramadol Capsules IP 50 mg	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Average net content	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight	
			Related substances (by HPLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
27	33	Tramadol Injection 50 mg/ ml	Description	
			Identification (by HPLC)	
			pH	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
28	34	Adrenaline Injection IP 1mg/ml (IM/IV use)	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Appearance of solution	
			pH	
			Noradrenaline (by HPLC)	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
29	35	Betamethasone Tablets IP 0.5mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (by TLC)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
30	37	Chlorpheniramine Maleate Tablets IP 4 mg	Description	
			Identification (by TLC)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by UV)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by UV)	
31	39	Dexamethasone Injection IP 8 mg/2ml	Description	
			Identification (by HPLC)	
			pH	
			Free Dexamethasone (by HPLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate Matter	
			Assay (by HPLC)	
			Sterility	
32	40	Dexamethasone Tablets IP 0.5mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Identification C (Chemical)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
33	42	Hydrocortisone Sod. Succinate Injection IP 100 mg base / vial (IM/IV use)	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Average weight	
			Uniformity of weight	
			Particulate matter	
			Clarity of solution A and B	
			Assay (by UV)	
			Sterility	
34	43	Hydroxyzine Tablets IP 25 mg	Description	
			Identification A (by HPLC)	
			Identification B (by TLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by HPLC)	
35	44	Methyl Prednisolone Sodium Succinate for Injection USP 500 mg	Description	
			Constituted solution	
			Identification (by IR)	
			Average net content	
			Uniformity of dosage units (weight variation)	
			pH	
			Loss on drying	
			Free methylprednisolone (by HPLC)	
			Bacterial endotoxins	
			Particulate matter (by liquid Particle counter)	
			Assay: (by HPLC)	
			Sterility	
36	45	Pheniramine Injection IP 22.75mg/ml	Description	
			Identification (by TLC)	
			pH	
			Related substances (by TLC)	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
37	47	Prednisolone Tablets IP 5 mg	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by UV)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
38	48	Promethazine Syrup IP 5mg/5ml	Description	
			Identification (by IR)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
39	49	Promethazine Injection IP 25mg/ml	Description	
			Identification A (by IR)	
			Identification B: Melting Point	
			Identification C (Chemical)	
			pH	
			Related substances (by TLC)	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by UV)	
			Sterility	
40	50	Promethazine Tablets IP 25 mg	Description	
			Identification A (by IR)	
			Identification B (Melting Range)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
41	51	Naloxone Injection IP 0.4mg/ ml	Description	
			Identification A (by HPLC)	
			Identification B (by TLC)	
			pH	
			Related substances (by TLC)	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
42	52	Pralidoxime Chloride Injection IP 500mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			Identification D (Chemical)	
			Average net content	
			Uniformity of weight	
			pH	
			Heavy metals	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Bacterial endotoxins	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
43	53	Carbamazepine Tablets IP 200 mg (Film Coated)	Description	
			Identification (by IR)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
44	54	Carbamazepine Tablets IP 100 mg (Film Coated)	Description	
			Identification (by IR)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
45	56	Phenobarbitone Tablets IP 30 mg	**Description**	
			Identification A (by IR)	
			Identification B (Chemical)	
			Disintegration	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Assay (Gravimetry)	
46	57	Phenytoin Injection 50mg/ml	Description	
			Identification A (by IR)	
			Identification D (Chemical)	
			Appearance of solution	
			Completeness of solution	
			pH	
			Heavy metals	
			Related substances (by TLC)	
			Water	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Bacterial endotoxins	
			Average weight	
			Particulate matter	
			Clarity of solution A and B	
			Contents of Packaged Dosage Forms	
			Assay: (by titration)	
			Sterility	
47	58	Phenytoin Oral suspension IP 25mg/ml	Description	
			Identification (by IR)	
			pH	
			Weight/ml	
			Contents of Packaged Dosage Forms	
			Benzil and benzophenone (by TLC)	
			Assay: (by Gravimetric)	
			Identification of colour	
			Microbial Examination	
			Total Aerobic Microbial Count	
			Total Combined Yeast & Mould Count	
			E. coli	
48	59	Phenytoin Tablets IP 100 mg (Film Coated)	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by TLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: Phenytoin sodium (titration)	
49	60	Sodium Valproate IP Injection 100 mg/ ml	Description	
			Identification A (by HPLC)	
			Identification B (Chemical)	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by GC)	
			Sterility	
50	61	Sodium Valproate Gastro resistant Tablets IP 200 mg	Description	
			Identification (by IR)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Uniformity of weight	
			Related substances (by GC)	
			Disintegration time	
			Content of package dosage form	
			Assay: by Chemical	
51	62	Acyclovir Oral Suspension IP 400mg/5ml	Description	
			Identification A (by UV)	
			Identification B (by TLC)	
			pH	
			Guanine (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Microbial Examination	
			Total Aerobic Count	
			Total fungal Count	
			E. coli	
52	63	Acyclovir Tablets IP 200 mg	Description	
			Identification A (by UV)	
			Identification B (by TLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Guanine (by TLC)	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
53	64	Acyclovir Tablets IP 800 mg	Description	
			Identification A (by UV)	
			Identification B (by TLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Guanine (by TLC)	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
54	65	Albendazole Oral suspension IP 400 mg/10ml	Description	
			Identification A (by UV)	
			Identification B (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification C (by HPLC)	
			pH	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Microbial Examination	
			Total Aerobic Count	
			Total fungal Count	
			E. coli	
55	66A	Albendazole Tablets IP 400 mg (Colour: Sunset Yellow FCF in suitable Flavoured Base)	Description	
			Identification A (by TLC)	
			Identification B (by UV)	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
56	67	Amikacin Injection IP 100 mg	Description	
			Identification A(by TLC)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Bacterial endotoxins	
			Related substances (by HPLC)	
			Particulate matter	
			Extractable volume	
			Assay: Microbiological assay	
			Sterility	
57	68	Amikacin Injection IP 500 mg	Description	
			Identification A(by TLC)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Bacterial endotoxins	
			Related substances (by HPLC)	
			Particulate matter	
			Extractable volume	
			Assay: Microbiological assay	
			Sterility	
58	69	Amoxycillin and Cloxacillin Capsules 250mg + 250 mg	Description	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification of:	
			Amoxicillin (by HPLC)	
			Cloxacilline (by HPLC)	
			Average net content	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Amoxycillin (by HPLC)	
			Cloxacilline (by HPLC)	
59	70	Amoxycillin and Potassium Clavulanate Tablets IP 500 mg + 125 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Water	
			Uniformity of content: Clavulanic acid (by HPLC)	
			Dissolution	
			Amoxycillin (by HPLC)	
			Clavulanic acid (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Amoxycillin (by HPLC)	
			Clavulanic acid (by HPLC	
60	71	Amoxycillin Capsules IP 250mg	Description	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
61	72	Amoxycillin Capsules IP 500mg	Description	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
62	73	Amoxycillin Dispersible Tablets IP 125mg	Description	
			Identification (by IR)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Uniformity of weight	
			Uniformity of dispersion	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
63	74	Amphotericin B Injection IP 50 mg	Description	
			pH	
			Loss on drying	
			Bacterial endotoxins	
			Average weight	
			Uniformity of weight	
			Particulate matter	
			Clarity of solution A and B	
			Assay: (by Microbiological assay)	
			Sterility	
64	75	Ampicillin Injection IP 500 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Identification C (Chemical)	
			Appearance of solution (by UV)	
			pH	
			Specific optical rotation	
			Related substances (by HPLC)	
			N,N-Dimethylaniline (by GC)	
			Dichloromethane (by GC)	
			Heavy metals	
			Bacterial endotoxins	
			Water	
			Average net content	
			Uniformity of weight	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility (MF)	
65	78A	Azithromycin Tablets 100 mg Dispersible Tablets	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Disintegration time	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of dispersion	
			Assay: (by HPLC)	
66	79A	Azithromycin Tablets IP 250 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
67	80A	Azithromycin Tablets IP 500 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
68	81	Benzathine Benzylpenicillin Injection IP 12 lac units	Description	
			Identification A (Chemical)	
			Identification B Melting point	
			Identification C (by HPLC)	
			pH	
			Consistency	
			Related substances (by HPLC)	
			Water	
			Bacterial endotoxins	
			Average weight	
			Uniformity of weight	
			Assay: (by HPLC)	
			Sterility	
69	82	Benzathine Benzylpenicillin Injection IP 6 lac units	Description	
			Identification A	
			Identification B Melting point	
			Identification C (by HPLC)	
			pH	
			Consistency	
			Related substances (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Water	
			Bacterial endotoxins	
			Average weight	
			Uniformity of weight	
			Assay: (by HPLC)	
			Sterility	
70	84	Cefixime Tablets IP 100 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Water	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
71	85	Cefixime Tablets IP 200 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Water	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
72	86	Cefoperazone and Sulbactum for Injection Cefoperazone Sodium eq. to Cefoperazone 1 g and Sulbactum Sodium eq. to Sulbactum 0.5 g (IM/ IV use)	Description	
			Identification of:	
			Cefoperazone sodium (by HPLC)	
			Sulbactam sodium (by HPLC)	
			Average net content	
			Uniformity of weight	
			Clarity of solution test a and b	
			Particulate matter	
			Bacterial endotoxins	
			Assay:	
			Cefoperazone (by HPLC)	
			Sulbactam (by HPLC)	
			Sterility	
73	87	Cefotaxime Injection 1gm	Description	
			Identification A (by HPLC)	
			Identification B (chemical)	
			Average net content	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Water	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
74	88	Cefotaxime Injection IP 250 mg	Description	
			Identification A (by HPLC)	
			Identification B	
			Average net content	
			Uniformity of weight	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Water	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
75	89	Ceftazidime Injection IP 1 gm	Description	
			Identification A (by HPLC))	
			Identification B (Chemical)	
			Average net content	
			Uniformity of weight	
			pH	
			Bacterial endotoxins	
			Pyridine (by HPLC)	
			Sodium carbonate (by FP/AAS)	
			Loss on drying	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
76	90	Ceftazidime Injection IP 250 mg	Description	
			Identification A (by HPLC))	
			Identification B	
			Average net content	
			Uniformity of weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			pH	
			Bacterial endotoxins	
			Pyridine (by HPLC)	
			Sodium carbonate (by FP)	
			Loss on drying	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
77	91	Ceftazidime Injection IP 500 mg	Description	
			Identification A (by HPLC))	
			Identification B	
			Average net content	
			Uniformity of weight	
			pH	
			Bacterial endotoxins	
			Pyridine (by HPLC)	
			Sodium carbonate (by FP/AAS)	
			Loss on drying	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
78	93	Ceftrioxone Injection IP 1gm /vial	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Identification C (Chemical)	
			Appearance of solution	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Water	
			Average weight	
			Uniformity of weight	
			Particulate matter	
			Clarity of solution A and B	
			Assay: (by HPLC)	
			Sterility	
79	94	Ceftrioxone Injection IP 250 mg/ vial	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification C	
			Appearance of solution	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Water	
			Average weight	
			Uniformity of weight	
			Particulate matter	
			Clarity of solution A and B	
			Assay: (by HPLC)	
			Sterility	
80	95	Ceftrioxone Injection IP 500mg/vial	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Identification C	
			Appearance of solution	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Water	
			Average weight	
			Uniformity of weight	
			Particulate matter	
			Clarity of solution A and B	
			Assay: (by HPLC)	
			Sterility	
81	96	Cephalexin Capsules IP 250 mg	**Description**	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Water	
			Assay: (by HPLC)	
82	97	Cephalexin Capsules IP 500 mg	**Description**	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Water	
			Assay: (by HPLC)	
83	98	Chloroquine Phosphate Injection IP 40mg/ml	Description	
			Identification A (by IR)	
			Identification B: Melting Point	
			Identification C (Chemical)	
			pH	
			Extractable volume	
			Particulate matter	
			Assay: (by titration)	
			Sterility	
84	99	Chloroquine Phosphate Tablets IP 250mg (Eq to 155 mg of Chloroquine base) (Film Coated)	Description	
			Identification A (by IR)	
			Identification B: Melting Point	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by TLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
85	100A	Chloroquine Phosphate Suspension IP 50 mg/5ml	Description	
			Identification (by IR)	
			pH	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour (by TLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
86	101	Ciprofloxacin Injection IP 200mg/100ml	Description	
			Identification (by TLC)	
			pH	
			Ciprofloxacin ethylenediamine analog (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Lactic acid (by HPLC)	
			Bacterial endotoxins	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
			Additional test:	
			Dextrose (by Optical rotation)	
			Sodium chloride (titration)	
87	102	Ciprofloxacin Tablets IP 250 mg (Film Coated)	Description	
			Identification A (by HPLC)	
			Identification B (by TLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
88	103	Ciprofloxacin Tablets IP 500 mg (Film Coated)	Description	
			Identification A (by HPLC)	
			Identification B (by TLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
89	104	Clotrimazole Cream IP 2% w/w	Description	
			Identification A (by HPLC)	
			Identification B (by TLC)	
			2-Chlotritanol (by HPLC)	
			Content of package dosage forms	
			Assay: (by HPLC)	
90	105	Clotrimazole Vaginal Tablets IP 500 mg	Description	
			Identification A (by HPLC)	
			Identification B (by TLC)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Disintegration time	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Content of package dosage form	
			Assay: (by HPLC)	
91	106	Compound Benzoic Acid Ointment IP [Benzoic Acid 6%+ Salicylic Acid 3%]	Description	
			Identification (by TLC)	
			Content of package dosage form	
			Assay:	
			For Benzoic acid (by titration)	
			For Salicylic acid (by UV)	
92	107	Co-trimoxazole Oral suspension IP Each 5 ml contains Trimethoprim 40 mg and Sulphamethoxazole 200 mg	Description	
			Identification (by TLC)	
			Weight per ml	
			pH	
			Contents of Packaged Dosage Forms	
			Identification of colour (by TLC)	
			Assay:	
			Sulphamethoxazole (by HPLC)	
			Trimethoprim (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
93	108	Co-trimoxazole Tablets IP Trimethoprim 40 mg and Sulphamethoxazole 200 mg	Description	
			Identification A (by IR)	
			Identification B (by IR)	
			Identification C (by TLC)	
			Average weight	
			Contents of Packaged Dosage Forms	
			Uniformity of weight	
			Disintegration Time	
			Assay:	
			Trimethoprim (by HPLC)	
			Sulphamethoxazole (by HPLC)	
94	110	Diethylcarbamazine Tablets IP 100 mg	Description	
			Identification (by IR)	
			Average weight	
			Uniformity of weight	
			N,N'-Dimethylpiperazine and N-methylpiperazine (by TLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
95	111	Doxycycline Capsules IP 100 mg	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Light absorbing impurities (by UV)	
			Average net content	
			Uniformity of weight	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Loss on drying	
			Assay: (by HPLC)	
96	114A	Fluconazole Tablets IP 150mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
97	116	Gentamicin Injection IP 80mg/2ml (IM/ IV use)	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			pH	
			Composition of gentamicin sulphate (by HPLC)	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by Microbiological)	
			Sterility	
98	117	Griseofulvin Tablets IP 125 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C: (Chemical)	
			Average weight	
			Uniformity of weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution (by UV)	
			Related substances (by GC)	
			Contents of Packaged Dosage Forms	
			Assay: By UV	
99	118	Itraconazole Capsules 100 mg	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
100	119	Meropenem Injection IP 500 mg	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			pH	
			Related Substances (by HPLC)	
			Content of Sodium (by FP/AAS)	
			Bacterial endotoxins	
			Loss on drying	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
101	120	Metronidazole Injection IP 500 mg/100ml	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter (by liquid particle counter)	
			Assay: (by UV)	
			Sterility	
102	121	Metronidazole Benzoate Oral Suspension IP 100 mg of base/5ml	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Metronidazole (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
103	122	Metronidazole Tablets IP 200 mg (Film Coated)	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C: Melting Point	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: Metronidazole (Titration)	
104	123	Metronidazole Tablets IP 400 mg (Film Coated)	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C: Melting Point	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by Titration)	
105	124	Norfloxacin Tablets IP 400 mg (Film Coated)	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
106	125	Ofloxacin Tablets IP 200 mg	Description	
			Identification (by HPLC)	
			Average weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
107	128	Primaquine Tablets IP 2.5 mg	Description	
			Identification A (by IR)	
			Identification B	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
108	129	Primaquine Tablets IP 7.5 mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
109	131	Quinine Dihydrochloride Injection IP 300 mg/ ml	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Other cinchona alkaloids (by HPLC)	
			Particulate matter	
			Extractable volume	
			Assay: (by Titration)	
			Sterility	
110	132	Quinine sulphate Tablets IP 300mg (Film Coated)	**Description**	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Identification C (Optical rotation)	
			Identification D (Chemical)	
			Average weight	
			Uniformity of weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution (by UV)	
			Other cinchona alkaloids (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: Quinine sulphate (Titration)	
			Identification of colour	
111	133	Azathioprine Tablets IP 50 mg	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			5-chloro-1-methyl-4-nitroimidazole and 6-mercaptopurine (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
112	134	Bleomycin Injection IP 15 mg (Bleomycin Sulphate Injection 15 units)	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			PH	
			Average fill weight	
			Copper	
			Method A-by UV	
			Uniformity of Weight	
			Content Of Bleomycin (By HPLC)	
			Bacterial Endotoxins	
			Clarity of solution A and B	
			Particulate Matter	
			Loss on drying	
			Sterility	
			Assay- by Microbial	
113	136	Chlorambucil Tablets IP 5 mg	Description	
			Identification (Chemical)	
			Average weight	
			Disintegration Time	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
114	137	Cisplatin Injection IP/BP 50 mg/50ml	Description	
			Identification A by UV	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification B by HPLC	
			pH	
			Tri Chloroammineplatinate by HPLC	
			Transplatine by HPLC	
			Bacterial Endotoxins	
			Sterlity	
			Extractable volume	
			Particulate Matter	
			Assay by HPLC	
115	138	Cyclophosphamide Injection IP 200 mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Related Substances (by TLC)	
			Bacterial Endotoxins	
			Average net content	
			Uniformity of weight	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
116	139	Cyclophosphamide Injection IP 500 mg	Description	
			Identification A (by IR)	
			Identification B	
			Identification C	
			pH	
			Related Substances (by TLC)	
			Bacterial Endotoxins	
			Average net content	
			Uniformity of weight	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
117	141	Cytarabine Injection BP 500mg	Description	
			Identification (by IR)	
			pH	
			Related substances (by TLC)	
			Particulate matter	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Extractable volume	
			Bacterial endotoxins	
			Water	
			Assay: (by titration)	
			Sterility	
118	142	Danazol Capsules IP 50 mg	Description	
			Identification (by IR)	
			Average net content	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
119	143	Daunorubicin Injection IP 20 mg	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			pH	
			Water	
			Clarity of solution test a and b	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
120	144	Doxorubicin Injection IP 50 mg/ 25 ml	Description	
			Identification (by HPLC)	
			pH	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
120	144	Doxorubicin Injection IP 50 mg/ 25 ml	Description	
			Identification (by HPLC)	
			Average Net Content	
			Uniformity of weight	
			pH	
			Bacterial endotoxins	
			Water	
			Clarity of solution test a and b	
			Particulate matter	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by HPLC)	
			Sterility	
121	146	Etoposide Injection IP 100 mg	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			pH	
			cis-Etoposide (by HPLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
122	147	Flunarizine Tablets 5 mg	Description	
			Identification (by UV)	
			Average weight	
			Disintegration Time	
			Uniformity of content (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
123	148	Fluorouracil Injection IP 250 mg/ 5ml	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			pH	
			Related Substances (by TLC)	
			Urea (by TLC)	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by UV)	
			Sterility	
124	149	L-Asparaginase Injection 10000 IU	Description	
			Identification A by Fermentive activity	
			Identification B by chemical test	
			Constituted solution	
			Completeness of solution	
			Clarity of solution	
			Colour of solution (UV)	
			Uniformity of dosage unit (weight variation)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight	
			Particulate matter by liquid particle size analyser	
			Average Net Content	
			pH	
			Bacterial endotoxins	
			Sterility	
			Water	
			Reconstitution time	
			Content of Amino acetic acid	
			Content of Protein	
			Fermentive activity	
			Specific gravity	
125	150	Leucovorin Calcium Injection IP/Calcium Folinate Injection IP 10 mg /ml	Description	
			Identification (by IR)	
			pH	
			Related Substances (by HPLC)	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
126	151	Melphalan Tablets IP 5 mg	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of content (by HPLC)	
			Disintegration time	
			Content of package dosage forms	
			Assay: (by HPLC)	
127	152	Mercaptopurine Tablets IP 50 mg	Description	
			Identification (by UV)	
			Average weight	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
128	153	Methotrexate Injection IP 50 mg/ 2 ml	Description	
			Identification (by UV)	
			pH	
			Related Substances (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Particulate matter	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
129	154	Methotrexate Tablets IP 2.5 mg	Description	
			Identification A (by UV)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Content of package dosage forms	
			Assay: (by HPLC)	
130	155	Paclitaxel Injection IP 260 mg	Description	
			Identification (by HPLC)	
			pH	
			light absorption (by UV)	
			Related Substances (by HPLC)	
			Particulate matter	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
131	156	Paclitaxel Injection IP 100 mg	Description	
			Identification (by HPLC)	
			pH	
			light absorption (by UV)	
			Related Substances (by HPLC)	
			Particulate matter	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
132	157	Tamoxifen Tablets IP 10 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (by TLC)	
			Identification D (by Chemical)	
			E-Isomer and related Substances (by HPLC)	
			Average weight	
			Uniformity of content (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration time	
			Content of package dosage forms	
			Assay: (by UV)	
133	158	Vinblastine Injection IP 10mg	Description	
			Identification A (by UV)	
			Identification B (TLC)	
			Identification C (by Chemical)	
			pH	
			Related Substances (by TLC)	
			Average Net Content	
			Uniformity of weight	
			Clarity of Solution A and B	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by UV)	
			Sterility	
134	159	Vincristine Injection IP 1 mg (Vial) / Vincristine Injection USP 1 mg/ml (Amp)	**Vincristine Injection USP**	
			Description	
			Identification A (by HPLC)	
			Identification B (Chemical)	
			Appearance of solution	
			Uniformity of weight	
			Ph	
			Related Substances (by HPLC)	
			Uniformity of Content (UV)	
			Clarity of solution test a and b	
			Particulate matter (by Liquid particle analyser)	
			Average Net content	
			Bacterial endotoxins	
			Assay: (by UV)	
			Sterility	
135	160	Levodopa and Carbidopa Tablets IP [Levodopa 100mg + Carbidopa 10 mg]	Description	
			Identification A (by HPLC)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Uniformity of content:	
			Carbidopa (by HPLC)	
			Average weight	
			Uniformity of weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration time	
			Content of package dosages forms	
			Assay:	
			For Levodopa (by HPLC)	
			For Carbidopa (by HPLC)	
136	161	Levodopa 250mg and Carbidopa 25 mg Tablets IP	Description	
			Identification A (by HPLC)	
			Identification B	
			Identification C	
			Uniformity of weight	
			Uniformity of Content of Carbidopa by HPLC (if applicable)	
			Average weight	
			Disintegration time	
			Content of package dosages forms	
			Assay:	
			For Levodopa (by HPLC)	
			For Carbidopa (by HPLC)	
137	162	Trihexyphenidyl Hydrochloride Tablets IP 2 mg	Description	
			Identification A (Chemical)	
			Identification B (by TLC)	
			Uniformity of content (by HPLC)	
			Average weight	
			Disintegration time	
			Content of package dosages forms	
			Assay: (by HPLC)	
138	163	Acenocoumarol Tablets IP 2 mg (Nicoumalone Tablets IP)	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by UV)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
139	165	Deferasirox Tablets 100 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration time	
			Assay: (by HPLC)	
140	166	Deferasirox Tablets 500 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	
141	167	Deferiprone Capsules 250 mg	Description	
			Identification (by UV)	
			Average net content	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Water	
			Dissolution (by UV)	
			Assay: (by UV)	
142	168	Deferiprone Capsules 500 mg	Description	
			Identification (by UV)	
			Average net content	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Water	
			Dissolution (by UV)	
			Assay: (by UV)	
143	169	Desferrioxamine Injection IP 500 mg / Vial (For I.M. Injection and I.V., S.C. Infusion)	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by UV)	
			Sterility	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
144	171	Dried Human Anti haemophlic Fraction IP (Dried Factor VIII Fraction IP) 250 IU/ Vial (IV use)		
145	172	Enoxaparin Sodium Injection IP 60 mg	Description	
			Identification A (Chemical)	
			Identification B (by UV)	
			Identification C (Chemical)	
			PH	
			Benzyl Alcohol (If Present)	
			Free Sulphate (Ion Chromatography)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (Anti Factor Xa activity)	
			(Anti Factor IIa activity)	
			Anti factor Xa to Anti Factor Iia ratio	
			Sterility	
146	173	Ethamsylate Injection 250 mg/ 2ml (IM/IV)	Description	
			Identification (by UV)	
			pH	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
147	174	Heparin Sodium Injection IP 5000 IU/ml [IM/IV Use]	NIB	
148	175	Human Albumin Solution IP 20%	NIB	
149	176	Rh-Erythropoetin Injection 10000 IU	NIB	
150	177	rh-Erythropoetin Injection 2000IU	NIB	
151	179	Rh-Erythropoetin Injection 4000 IU	NIB	
152	180	Vitamin K Injection Each ml Contains Menadione Sodium Bisulphite 10 mg Equivalent to 5.2 mg of Menadione. (Aqueous Solution)	Description	
			Identification A (by HPLC)	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
153	181	Amiodarone Tablets IP 100 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
154	182	Amiodarone Tablets IP 200 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
155	183	Amiodarone Hydrochloride Injection 50 mg/ml	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Appearance of solution	
			Related substances (by TLC)	
			Iodide (by UV)	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
156	184	Amlodipine Tablets IP 2.5 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
157	185	Amlodipine Tablets IP 5 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
158	186	Atenolol Tablets IP 50 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
159	187	Atorvastatin Tablets IP 10 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Related substances (by HPLC)	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
160	188	Clopidogrel Tablets IP 75 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
161	189	Digoxin Injection IP 0.25 mg/ml	Description	
			Identification (Chemical)	
			pH	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by UV)	
			Sterility	
162	190	Digoxin Tablets IP 0.25 mg.	Description	
			Identification (Chemical)	
			Average weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of Content (by UV)	
			Dissolution B (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
163	191	Diltiazem Tabletss IP 30 mg (Film Coated)	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution B (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
164	192	Dobutamine Injection IP/BP 250 mg (Vial) / Dobutamine Injection USP 250 mg/5ml (Amp) (Liquid form)	Description	
			Identification (by HPLC)	
			pH	
			Appearance of solution	
			Light absorption (by UV)	
			Related substances (by HPLC)	
			Particulate matter	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
164	192	Dobutamine Injection IP/BP 250 mg (Vial) / Dobutamine Injection USP 250 mg/5ml (Amp) (Powder Form)	Description	
			Identification (by HPLC)	
			Average Net Content	
			Uniformity of weight	
			pH	
			Appearance of solution	
			Light absorption (by UV)	
			Related substances (by HPLC)	
			Particulate matter	
			Clarity of solution test a and b	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
165	193	Dopamine Hydrochloride Injection 40 mg/ml	Description	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification A (by IR)	
			Identification B (Chemical)	
			pH	
			5-Hydroxymethylfurfural (by HPLC)	
			Related substances (by HPLC)	
			Particulate matter	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
166	194	Enalapril Maleate Tablets IP 5mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
167	195	Enalapril Maleate Tablets IP 2.5mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
168	197	Isosorbide dinitrate Tablets IP 5 mg	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Inorganic nitrate (by TLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
169	198	Isosorbide mononitrate Tablets IP 20 mg	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Inorganic nitrate (by TLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Related substances (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
170	199	Lisinopril Tablets IP 5 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
171	200	Losartan Tablets IP 50 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
172	201	Magnesium Sulphate Injection IP 500mg/ml (50% w/v)	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			pH	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by Chemical)	
			Sterility	
173	202	Methyldopa Tablets IP 250mg Film Coated	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			Identification D (Chemical)	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Optical rotation	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification of colour	
174	203	Nifedipine capsules IP 5mg	Description	
			Identification (by TLC)	
			Average net content	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Uniformity of content (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
175	204	Nifedipine Tablets IP 10 mg (Sustained Release)	Description	
			Identification (by TLC)	
			Average weight	
			Dissolution A (by UV)	
			Dissolution B (by UV)	
			Uniformity of content (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
176	205	Nitroglycerin Injection 5 mg/ ml	Description	
			Identification (by HPLC)	
			pH	
			Ethanol determination (by GC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter (by particle size analyser)	
			Assay: (by HPLC)	
			Sterility	
177	207	Propranolol Tablets IP 40 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
178	209	Streptokinase Injection IP 15 lac units	NIB	
179	211	Verapamil Tablets IP 40 mg (Film Coated)	Description	
			Identification A (by IR)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification B (by Chemical)	
			Identification C (by Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
180	213	Acyclovir Cream 5%	Description	
			Identification (by UV)	
			Identification (by TLC)	
			Guanine (by TLC)	
			Uniformity of weight (mass)	
			Assay: (by UV)	
181	215A	Cetrimide Cream IP	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Contents of Packaged Dosage Forms	
			Assay: Cetrimide (titration)	
182	216A	Fusidic Acid Cream IP 2%	Description	
			Identification A (By TLC)	
			Identification B (By HPLC)	
			Ph	
			Related Substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: By HPLC	
183	217	Glycerin IP	Description	
			Identification B	
			Identification C	
			Identification D: Refractive index	
			Appearance of solution	
			Acidity or alkalinity	
			Heavy metals	
			Iron	
			Chlorides	
			Sulphates	
			Aldehydes and reducing substances	
			Ester	
			Ethylene glycol, diethylene glycol and related substances (by GC)	
			sugars	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Sulphated ash water Net content **Assay:** Glycerin (Titration)	
184	218	Liquid Paraffin IP	Description	
			Weight per ml	
			Dynamic viscosity	
			Acidity or alkalinity	
			Light absorption (by UV)	
			Readily Carbonisable substances	
			Solid paraffins	
			Sulphur compounds	
			Net content	
185	219	Ointment containing : Lidocaine IP 3%, Zinc oxide IP 5% , Hydrocortisone IP 0.25%, Allantoin IP 0.5%	Description	
			Identification of:	
			Lidocaine	
			Hydrocortisone	
			Zinc	
			Allantoin	
			Contents of Packaged Dosage Forms	
			Assay:	
			Lidocaine	
			Hydrocortisone (by UV)	
			Zinc oxide	
			Allantoin (by UV)	
186	220	Miconazole Nitrate Cream IP 2%	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by GC)	
187	221	Povidone Iodine Ointment 5%	Description	
			Identification A	
			Identification B	
			Minimum fill	
			pH	
			Assay: (by potentiometer)	
188	222	Povidone Iodine solution IP 5%	Description	
			Identification A	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification B	
			Identification C	
			Contents of Packaged Dosage Forms	
			pH	
			Assay: Povidone iodine (Blank Titration)	
189	223	Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg)	Description	
			Identification of:	
			Neomycin sulphate	
			Bacitracin zinc	
			Sulphacetamide	
			Contents of Packaged Dosage Forms	
			Assay:	
			Neomycin (by Microbiological assay)	
			Bacitracin (by Microbiological assay)	
			Sulphacetamide (by UV)	
190	224	Silver Sulphadiazine cream IP 1%	Description	
			Identification (by TLC)	
			pH	
			Contents of Packaged Dosage Forms	
			Microbial contamination	
			Escherichia coli	
			Staphylococcus species	
			Pseudomonas aeruginosa	
			Salmonella species	
			Shigella	
			Assay: (by HPLC)	
191	225	Anti A Blood Grouping Serum IP (Anti A Monoclonal Serum)	NQ	
192	226	Anti B Blood Grouping Serum IP (Anti B Monoclonal Serum)	NQ	
193	227	Anti D (Rh) Blood Grouping Serum IP / Anti D Blood Grouping Serum IP	NQ	
194	232	Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 60% (iodine conc = 292 mg/ml)	Description	
			Identification A (by TLC)	
			Identification B	
			Bacterial endotixins	
			pH	
			Free aromatic amine	
			Iodine and Iodide	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Heavy metals	
			Sterility	
			Extractable volume	
			Particulate matter	
			Assay	
			For Diatrizoate meglumine (Optical Rotation)	
			For Iodine	
195	233	Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 76%w/v (iodine conc =370 mg/ml)	Description	
			Identification A (by TLC)	
			Identification B	
			Bacterial endotixins	
			pH	
			Free aromatic amine	
			Iodine and Iodide	
			Heavy metals	
			Sterility	
			Extractable volume	
			Particulate matter	
			Assay	
			For Diatrizoate meglumine (Optical Rotation)	
			For Iodine	
196	235	Gadodiamide Injection 0.5 mmol/ml Vial	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Organic impurities (by HPLC)	
			Osmolality and Osmolarity	
			pH	
			Particulate contamination	
			Bacterial endotoxins	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
197	241	Tropicamide Eye Drops IP 1%	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			pH	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by UV)	
			Sterility	
198	242	VDRL Antigen (with +ve and -ve control) / RPR slide Kit	NIB	
199	244	Compound Benzoin Tincture IP	Description	
			Identification A- (By TLC)	
			Identification B- (By TLC)	
			Identification C- (By TLC)	
			Identification D- (By TLC)	
			Weight per ml	
			Ethanol Content	
			Total Solid	
			Contents of Packaged dosage Forms: Container Content	
			Assay (chemical)	
200	245	Formaldehyde Solution (34.5% - 38%)	Description	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay: (by titration method)	
201	246	Gentian Violet Topical Solution USP 1%	Description	
			Identification A	
			Identification B	
			Solution of residue in alcohol	
			Net content	
			Alcohol content	
			Assay: Gentian violet (by titration)	
202	247	Gluteraldehyde solution 2 %	Description	
			Identification A (Chemical)	
			Net Content	
			Mercury Compound	
			Weight per ml	
			pH	
			Assay:	
203	248	Hydrogen Peroxide Solution IP 6% (20 Vol)	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Acidity	
			Organic stablizers	
			Non-volatile matter	
			Volume in container	
			Assay: Hydrogen peroxide (Chemical)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
204	249	Lysol (Cresol with Soap Solution) IP Cresol 50% + Soap 50%	Description	
			Appearance of solution	
			Alkalinity	
			Hydrocarbons and volatile bases	
			Hydrocarbons	
			Volatile bases	
			Volume in container	
			Sulphur compounds	
			Assay: Cresol	
205	250	Povidone Iodine Scrub Solution / cleansing solution 7.5% w/v Povidone Iodine (suiTabletsle for hand wash)	Description	
			Identification A	
			Identification B	
			Net content	
			pH	
			Assay: Povidone iodine	
206	252	Surgical Spirit IP/BP	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Weight/ml	
			Net content	
			Assay:	
			For Methyl Salisylate (by UV)	
			For Diethyl Phthalate (by UV)	
207	253	Acetazolamide Tablets IP 250mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: Acetazolamide (Chemical)	
208	254	Frusemide Tablets IP 40 mg.	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
209	255	Furosemide Injection IP 10mg/ml (IM & IV use)	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			pH	
			Related substances (by HPLC)	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by UV)	
			Sterility	
210	256	Hydrochlorthiazide Tablets IP 12.5 mg	Description	
			Identification (by TLC)	
			Average weight	
			Dissolution (by UV)	
			Uniformity of weight/Uniformity of Content by UV (as applicable)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
211	257A	Mannitol Injection IP 20% w/v	Description	
			Identification A (by melting point)	
			Identification B (by TLC)	
			Identification C (Chemical)	
			pH	
			Particulate contamination (by particle counter)	
			Bacterial endotoxins	
			Extractable volume	
			Assay: (by titration)	
			Sterility	
212	258	Spironolactone Tablets IP 25 mg	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Identification C	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
213	259	Torsamide Tablets 10 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
214	260A	Antacid Tablets Formula: Each chewable Tablets contains Magnesium Trisilicate 250mg, Dried Aluminium Hydroxide Gel 120mg, Peppermint oil	Description	
			Identification of:	
			Aluminum	
			Magnesium	
			Average weight	
			Uniformity of weight	
			Acid neutralizing capacity	
			Contents of Packaged Dosage Forms	
			Assay:	
			Dried aluminium hydroxide gel (titration)	
			Magnesium trisilicate (titration)	
			Identification of colour (by TLC)	
215	261A	Antacid Liquid Each 5ml contains Dried Aluminium Hydroxide Gel 250 mg, Magnesium Hydroxide 250mg, Activated polydimethyl siloxane 50mg	Description	
			Identification of:	
			Aluminium	
			Magnesium	
			Polydimethylsiloxane (by IR)	
			pH	
			Acid neutralizing capacity	
			Contents of Packaged Dosage Forms	
			Assay:	
			Dried aluminium hydroxide gel (titration)	
			Magnesium hydroxide (titration)	
			Polydimethylsiloxane (by IR)	
			Identification of colour (by TLC)	
			Microbial Examination	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Total aerobic count	
			Total fungal count	
			E. coli	
216	262	Bisacodyl Tablets IP 5 mg	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
217	263	Dicyclomine Tablets IP 10 mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Related substances (by TLC)	
			Disintegration time	
			Uniformity of content	
			Contents of Packaged Dosage Forms	
			Assay: Dicyclomine Hydrochloride (Chemical)	
218	264	Dicyclomine Injection IP 10 mg /ml	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
219	265	Dicyclomine Hydrochloride Oral Solution IP 10mg /5ml	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay: Dicyclomine Hydrochloride (Chemical)	
			Identification of colour	
			Microbiological Examination	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Total Aerobic count	
			Total Fungal count	
			E. coli	
220	266	Domperidone Suspension IP 5mg/5ml	Description	
			Identification (by HPLC)	
			Contents of Packaged Dosage Forms	
			Identification of colour (by TLC)	
			Assay: (by HPLC)	
			Microbiological Examination	
			Total Aerobic count	
			Total Fungal count	
			E. coli	
221	267	Domperidone Tablets IP 10 mg	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Average weight	
			Dissolution (by UV)	
			Uniformity of content (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
222	268	Hyoscine Butylbromide Injection IP 20 mg/ ml	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			pH	
			Hyoscine (by HPLC)	
			Related substances (by TLC)	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
223	269	Loperamide Tablets IP 2 mg	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
224	270	Metoclopramide Injection IP 10mg/2ml	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by UV)	
			Sterility	
225	271	Metoclopramide Tablets IP 10 mg	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Average weight	
			Related substances (by HPLC)	
			Disintegration time	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
226	272	Omeprazole Capsules IP 20 mg	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of content (by HPLC)	
			Dissolution A (by HPLC)	
			Dissolution B (by HPLC)	
			Loss on drying	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
227	273	Ondansetron Injection IP 2mg/ml	Description	
			Identification (by HPLC)	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
228	274	ORS Powder IP	Description	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification A (Chemical)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Identification D (Chemical)	
			Contents of Packaged Dosage Forms	
			Seal test	
			Assay: (Chemical)	
			Total Sodium	
			Potassium	
			Citrate	
			Total chloride	
			Dextrose (Anhydrous)	
229	275	Pantoprazole Injection 40 mg	Description	
			Identification (by IR)	
			Average net content	
			Uniformity of Weight	
			Related Substances (By HPLC)	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
230	276	Ranitidine HCL Injection IP 50mg/2ml	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
231	277	Ranitidine Tablets IP 150mg (Film coated)	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification of colour	
232	278	Sodium Phosphates Enema BP Each 100ml contains Sodium Dihydrogen phosphate Dihydrate 10%, Disodium Hydrogen Phosphate Dodecahydrate 8%	Description	
			Identification A	
			Identification B	
			Clarity and colour of solution	
			Acidity: pH	
			Net content	
			Assay:	
			Sodium hydrogen phosphate	
			Disodium hydrogen phosphate	
233	279	Biphasic Isophane Insulin Injection IP (30% Soluble Insulin & 70% Isophane Insulin) Injection 40 IU/ml (r-DNA origin)	NQ	
234	280	Carbimazole Tabletss IP 5 mg (Film Coated)	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of content (by UV)	
			Thiamazole and other related substances (by HPLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
235	281	Carboprost Tromethamine Injection Each ml contains Carboprost 0.25mg/ml	Description	
			Identification by IR	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay by HPLC	
			Sterility (by MF)	
236	282	Clomifene Tablets IP 25 mg	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of weight	
			Z-isomer (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Contents of Packaged Dosage Forms	
			Dissolution (by UV)	
			Assay: (by UV)	
237	283	Clomiphene Tablets IP 50 mg	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of weight	
			Z-isomer (by HPLC)	
			Contents of Packaged Dosage Forms	
			Dissolution (by UV)	
			Assay: (by UV)	
238	284	Conjugated Estrogen Tablets USP 0.625 mg.	Description	
			Identification A (by GC)	
			Identification B (GC)	
			Average weight	
			Dissolution (By HPLC)	
			1st Stage	
			2nd stage	
			3rd Stage	
			4th Stage	
			Uniformity of content (byHPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by GC)	
239	285	Dinoprostone Cream/Gel 0.5 mg Dinoprostone in syringe	Description	
			Identification (by HPLC)	
			Uniformity of weight	
			Total viable count	
			Total bacterial count	
			Total fungal count	
			Pathogens	
			E. coli	
			Salmonella	
			S, aureus	
			P. auregonesa	
			Assay (by HPLC)	
240	286	Ethinyloestradiol Tablets IP 50 mcg	Description	
			Identification A (by TLC)	
			Identification B	
			Average weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of content (by HPLC)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
241	287	Glibenclamide Tablets IP 5 mg	Description	
			Identification A (by HPLC)	
			Identification B (by TLC)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by HPLC)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
242	288	Gliclazide Tablets IP 40 mg	Description	
			Identification (by IR)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
243	289	Glimepiride Tablets IP 2 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
244	290	Glimepiride Tablets IP 1 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
245	291	Glipizide Tablets IP 5mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Average weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration Time	
			Related substances (TLC)	
			Uniformity of content (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
246	293	Hydroxyprogesterone Injection IP 250mg/ ml	Description	
			Identification A (by TLC)	
			Identification B: Melting Point	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
247	294	Isophane Insulin Injection IP 40 IU/ml	NQ	
248	295	Metformin Tablets IP 500 mg (Film Coated)	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Dissolution (by UV)	
			Assay: (by UV)	
249	296	Norethisterone Tablets IP 5 mg	Description	
			Identification (by TLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
250	297	Pioglitazone Tablets IP 15 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight/Uniformity of Content by HPLC (as applicable)	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay **(**by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
251	298	Progesterone Injection IP 200 mg/ 2ml	**Progesterone Injection IP**	
			Description	
			Identification A (by IR)	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
251	298	Progesterone Injection IP 200 mg/ 2ml(suspension form)		
			Description	
			Identification A (by IR)	
			Identification B (Melting Point)	
			Ph	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
252	300	Insulin Injection IP (Soluble Insulin / Neutral Insulin Injection) 40 IU/ ml. (r-DNA origin)	NQ	
253	301	Thyroxine Sodium Tablets IP 100mcg	Description	
			Identification A (by Chemical)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	
254	303	Human Anti D Immunoglobulin Injection 300mcg (I.M.use)	NQ	
255	304	Human Anti D Immunoglobulin 150 mcg	NQ	
256	305	Human Rabies Immunoglobulin Injection 150 IU/ ml	NQ	
257	306	Rabies Vaccine Human (Cell Culture) IP (Intradermal) 2.5 IU	NQ	
258	307	Rabies Vaccine Human (Cell Culture) IP (Intramuscular) 2.5 IU/ dose	NQ	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
259	308	Snake Venum Anti Serum IP (Lyophilized) Polyvalent Anti Snake Venum, Serum Enzyme Refined. Contain purified equine globulins. 1 ml of serum neutralizes 0.6 mg of cobra venum, 0.45 mg of common kraite (Bungaras) venum, 0.6 mg of Russell's Viper Venom and 0.45 mg of Saw-scaled Viper Venom.	NQ	
260	309	Tetanus Immunoglobulin 250 IU/ Vial	NQ	
261	310	Tetanus Vaccine (adsorbed) I.P.	NQ	
262	311	Atracurium Injection 10 mg/ml	Description	
			Identification (by HPLC)	
			pH	
			Related substances (by HPLC)	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
263	312	Glycopyrrolate Injection USP 0.2 mg/ml	Description	
			Identification (by TLC)	
			pH	
			Volume in container (Extractable Volume)	
			Particulate matter by particle size analyzer	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
264	313	Midazolam Injection IP 1 mg/ml	Description	
			Identification (by IR)	
			pH	
			Related substances (by HPLC)	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
265	314	Neostigmine Injection IP 0.5 mg/ml	Description	
			Identification A (by UV)	
			Identification B (by TLC)	
			Identification C (Chemical)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			pH	
			3-Hydroxy trimethylanilinium methyl sulphate (by HPLC)	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
266	316	Neostigmine Tablets IP 15 mg	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of content (by titration)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by titration)	
267	317	Succinylcholine Injection IP 50 mg/ml (IV use)	Description	
			Identification (Chemical)	
			pH	
			Hydrolysis product (by titration)	
			Particulate matter	
			Extractable volume	
			Bacterial endotoxines	
			Assay: (by titration)	
			Sterility	
268	318	Valethamate Bromide Injection 8mg /ml	Description	
			Identification of Valethamate Bromide	
			pH	
			Particulate matter	
			Extractable volume	
			Assay:	
			Valethamate Bromide	
			Sterility	
269	319	Atropine Eye Ointment IP 1%	Description	
			Identification (by TLC)	
			Particle size	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Sterility	
270	320	Atropine Sulphate Ophthalmic Solution USP 1%	Description	
			Identification A (by HPLC)	
			Identification B	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Organic Impurities by HPLC	
			pH	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Sterility	
271	321	Chloramphenicol Eye Drops IP 0.5%	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			pH	
			Contents of Packaged Dosage Forms	
			Assay: by HPLC)	
			Sterility	
272	322	Ciprofloxacin Eye Drops 0.3% w/v	Description	
			Identification A (by HPLC)	
			Identification B (Chemical)	
			pH	
			Contents of Packaged Dosage Forms	
			Assay: by HPLC)	
			Sterility	
273	323	Ciprofloxacin Ophthalmic Ointment USP 0.3%	Description	
			Identification A (by HPLC)	
			Minimum fill	
			Metal particle in ophthalmic ointment	
			Assay: (by HPLC)	
			Sterility	
274	324	Hydroxypropylmethyl cellulose solution 20 mg/ ml	Description	
			Identification A	
			Identification B	
			pH	
			Net content	
			Assay: (by UV)	
			Sterility	
275	330	Tobramycin and Dexamethasone Ophthalmic Suspension USP 0.3%+0.1%	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			pH	
			Net content	
			Assay:	
			Tobramycin (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dexamethasone (by HPLC)	
			Sterility	
276	331	Tobramycin Eye Drops 0.3%	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			pH	
			Net content	
			Assay: (by HPLC)	
			Sterility	
277	332	Tobramycin Ophthalmic Ointment USP 0.3%	Description	
			Identification A (by TLC)	
			water	
			Minimum fill	
			Metal particles in ophthalmic ointment	
			Assay: (by HPLC)	
			Sterility	
278	333	Isoxsuprine Injection IP 5 mg/ml	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			pH	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by UV)	
			4	
279	334	Isoxsuprine Tablets IP 20 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
280	335	Methylergometrine Injection IP 0.2mg/ml	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Related substances (by TLC)	
			Bacterial endotoxins	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Particulate matter	
			Extractable volume	
			Assay: (by UV)	
			Sterility	
281	336	Methylergometrine Tablets IP 0.125 mg	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by UV)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
282	337	Misoprostol Tablets 200 mcg	Description	
			Identification A (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	
283	338	Oxytocin Injection IP 5 IU/ml	Description	
			Identification A (by HPLC)	
			pH	
			Bacterial endotoxins	
			Extractable volume	
			Vasopressin Impurity (HPLC)	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
284	339	Alprazolam Tablets IP 0.25 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
285	340	Alprazolam Tablets IP 0.5mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
286	341	Amitriptyline Tablets IP 25mg Film Coated	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by TLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
287	342	Chlordiazepoxide Tablets IP 10mg	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by UV)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
288	343	Chlorpromazine Tablets IP 100 mg (Coated Tablets)	Description	
			Identification A (by IR)	
			Identification B(by UV)	
			Identification C (Chemical)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
289	344	Chlorpromazine Tablets IP 25 mg (Sugar- Coated)	Description	
			Identification A (by IR)	
			Identification B(by UV)	
			Identification C	
			Average weight	
			Related substances (by TLC)	
			Uniformity of weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
290	345	Chlorpromazine Tabletss IP 50 mg. (Coated Tablets)	Description	
			Identification A (by IR)	
			Identification B(by UV)	
			Identification C	
			Average weight	
			Related substances (by TLC)	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
291	346	Chlorpromazine Injection IP 25mg/ml	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			Related substances (by TLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
292	349	Diazepam Injection IP 10mg/2ml (1M/IV use)	Description	
			Identification A (by TLC)	
			Identification B (by UV)	
			pH	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
293	350	Diazepam Tablets IP 5 mg	Description	
			Identification A (by TLC)	
			Identification B (by UV)	
			Average weight	
			Related substances & decomposition products (by TLC)	
			Contents of Packaged Dosage Forms	
			Uniformity of content (by UV)	
			Dissolution (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by UV)	
294	351	Escitalopram Tablets IP 10 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
295	352	Fluoxetine Capsules IP 20 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related Substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
296	353	Haloperidol Injection IP 5 mg/ml	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			pH	
			Related substances (by TLC)	
			Particulate matter	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by UV)	
			Sterility	
297	354	Haloperidol Tablets IP 1.5 mg	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Related substances (by TLC)	
			Average weight	
			Disintegration time	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
298	355	Haloperidol Tablets IP 5 mg	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Related substances (by TLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Disintegration time	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
299	356	Imipramine Tablets IP 25 mg (Coated Tablets)	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by TLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
300	357	Imipramine Tablets IP 75 mg (Coated)	Description	
			Identification A	
			Identification B	
			Identification C	
			Average weight	
			Uniformity of weight	
			Related substances (by TLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
301	358	Lithium Carbonate Tablets IP 300 mg	Description	
			Identification (Chemical)	
			Average weight	
			Uniformity of weight	
			Dissolution (by Flam photometer)	
			Contents of Packaged Dosage Forms	
			Assay: Chemical	
302	359	Lorazepam Injection 2 mg/ml	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Related substances (by TLC)	
			Bacterial endotoxins	
			Extractable volume	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
303	360	Olanzapine Tablets IP 5 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
304	361	Risperidone Tablets 2 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of dosage units (content uniformity: by HPLC)	
			Dissolution (by HPLC)	
			Related compound (by HPLC)	
			Assay: (by HPLC)	
305	362	Risperidone Tablets 1 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of dosage units (content uniformity: by HPLC)	
			Dissolution (by HPLC)	
			Related compound (by HPLC)	
			Assay: (by HPLC)	
306	363	Sertraline Tablets 50 mg	Description	
			Identification A (by IR)	
			Average weight	
			Uniformity Of weight	
			Dissolution (by HPLC)	
			Related Substances (HPLC)	
			Enatiomeric Purity	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
307	364	Trifluperazine Tablets IP 5 mg (Coated)	Description	
			Identification A (by IR)	
			Identification B (by Chemical)	
			Average weight	
			Uniformity of content (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
308	365	Aminophylline Injection IP 25 mg/ml	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Identification D: Melting Point	
			pH	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay:	
			Theophylline (by HPLC)	
			Ethylenediamine (Chemical)	
			Sterility	
309	366	Beclomethasone Inhalation IP 200 mcg/ dose	Description	
			Identification A- (by IR)	
			B- (by HPLC)	
			Related Substances (by TLC)	
			Nominal Net Weight	
			Number of deliveries per container	
			Uniformity of delivered dose	
			Content of Active Ingredient delivered per actuation	
			Acceptance Criteria	
			Particle size	
			Leak Test	
			deposition of the emitted dose	
			Assay (By HPLC)	
310	367	Budesonide Nebulizer Suspension 0.25mg/ ml	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			pH	
			Related substances (by HPLC)	
			Epimer A (by HPLC)	
			Nominal Volume	
			Average Net Volume	
			Uniformity of Volume	
			Assay: (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Microbial Examination	
			Total aerobic microbial count	
			Total combined yeast & moulds count	
			Staphylococcus aureus	
			Pseudomonas curuginesa	
			Bile-tolerant gram-negative bacteria	
311	368	Cough Syrup Each 5ml contains Chloropheniramine Maleate IP 3mg Ammonium Chloride 130mg, Sodium Citrate 65 mg, Menthol 0.5 mg, Syrup Q.S.	Description	
			Identification of:	
			Chlorpheniramine maleate	
			Ammonium salt	
			Sodium citrate	
			Chloride	
			Menthol	
			pH	
			Contents of Packaged Dosage Forms	
			Identification of colour	
			Assay:	
			Chlorpheniramine maleate (by UV)	
			Ammonium chloride	
			Sodium citrate (by FP)	
			Menthol (by UV)	
			Microbiological Examination	
			Total Aerobic count	
			Total Fungal count	
			E. coli	
312	369	Ipratropium Bromide Nebulizer Solution 250 mcg/ ml	Description	
			Identification (by HPLC)	
			(Acidity): pH	
			Contents of Packaged Dosage Forms	
			Assay: [by HPLC]	
			Microbial Examination	
			Total aerobic microbial count	
			Total Fungal count	
			Staphylococcus aureus	
			Pseudomonas curuginesa	
			Bile-tolerant gram-negative bacteria	
313	370	Salbutamol Tablets IP 4 mg	Description	
			Identification A (by TLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by HPLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
314	371	Salbutamol Inhalation 100 mcg /dose	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Average weight	
			Content of Active Ingredient delivered per actuation	
			Uniformity of delivered dose	
			Particle Size	
			Number of deliveries per container	
			leak test	
			deposition of the emitted dose	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
315	372	Salbutamol Nebuliser Solution BP 5 mg/ml	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Identification C	
			(Acidity): pH	
			Related Substances (by HPLC)	
			Assay: [by UV]	
			Salbutamol Ketones (by HPLC)	
			Microbial Examination	
			Content of Packaged Dosage form	
			Total aerobic microbial count	
			Total fungal count	
316	373	Salbutamol Tablets IP 2 mg	Description	
			Identification A (by TLC)	
			Identification B	
			Identification C	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
317	374	Theophylline and Etofylline Injection (Anhydrous Theophylline 50.6mg + Etofylline 169.4 mg)	**Description**	
			Identification of:	
			Etophylline (by HPLC)	
			Theophylline (by HPLC)	
			pH	
			Particulate matter	
			Extractable volume	
			Assay:	
			Etophylline (by HPLC)	
			Theophylline (by HPLC)	
			Sterility	
318	375	Theophylline and Etofylline Tablets (Theophylline IP 23mg + Etofylline IP 77 mg)	Description	
			Identification of:	
			Etophylline (by HPLC)	
			Theophylline (by HPLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of content of Theophylline by HPLC (if applicable)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Etofylline (by HPLC)	
			Theophylline (by HPLC)	
319	376	Theophylline Tablets 400 mg Sustained release/controlled release (Theophylline prolonged Release Tablets IP)	Description	
			Identification A (by HPLC)	
			Identification B	
			Average weight	
			Uniformity of weight	
			Related substances (by TLC)	
			Dissolution: (by UV)	
			1st time point	
			2nd time point	
			3rd time point	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
320	377	Compound Sodium Lactate Injection IP	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	
			Assay:	
			For sodium (by flame photometer)	
			For potassium (by flame photometer)	
			For total chloride	
			For calcium chloride	
			For lactate	
			Sterility	
321	378	Dextrose Injection IP 25 % w/v	Description	
			Identification A (Chemical)	
			Identification B (by optical rotation)	
			5-Hydroxymethylfurfural and related substances (by UV)	
			pH	
			Heavy metals	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by optical rotation)	
			Sterility	
322	379	Dextrose Injection IP 10%	Description	
			Identification A	
			Identification B (by optical rotation)	
			5-Hydroxymethylfurfural and related substances (by UV)	
			pH	
			Heavy metals	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by optical rotation)	
			Sterility	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
323	380	Dextrose Injection IP 5%	Description	
			Identification A	
			Identification B (by optical rotation)	
			pH	
			5-Hydroxymethylfurfural and related substances (by UV)	
			Heavy metals	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	
			Assay: (by optical rotation)	
			Sterility	
324	381	Multiple Electrolytes & Dextrose Injection Type I (Electrolyte 'P' Injection)	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			For acetate	
			For chloride	
			For phosphates	
			For sodium salts	
			For potassium salts	
			For magnesium salts	
			pH	
			5-Hydroxymethylfurfural and related substances (by UV)	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	
			Assay:	
			For sodium (by FP)	
			For total potassium (by FP)	
			For magnesium (Chemical)	
			For acetate (by HPLC)	
			For phosphates (by UV)	
			For total chloride (Chemical)	
			For dextrose (by optical rotation)	
			Sterility	
325	382	Multiple Electrolytes & Dextrose Injection Type III IP Electrolyte "M" Injection (I.V.)	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			For acetate	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			For chloride	
			For phosphates	
			For sodium salts	
			For potassium salts	
			pH	
			5-Hydroxymethylfurfural and related substances (by UV)	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	
			Assay:	
			For total sodium (by FP)	
			For potassium (by FP)	
			For acetate (by HPLC)	
			For phosphates (by UV)	
			For total chloride	
			For dextrose (by optical rotation)	
			Sterility	
326	383	Potassium Chloride Injection 0.15 gm/ml	Description	
			Identification	
			Acidity or alkalinity (pH)	
			Extractable volume	
			Bacterial endotoxins	
			Assay: Potassium Chloride	
			Sterility	
327	384	Potassium chloride Oral Solution U.S.P 500mg/ 5ml	Description	
			Identification A	
			Identification B	
			Minimum Fill	
			Uniformity of dosage unit	
			Assay: by AAS	
328	385	Sodium Chloride and Dextrose Injection I.P (0.9%+5%)	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Heavy metals	
			pH	
			5-Hydroxymethylfurfural and related substances (by UV)	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay:	
			For sodium chloride (Chemical)	
			For dextrose (by optical rotation)	
			Sterility	
329	386	Sodium Chloride Injection IP	Description	
			Identification (Chemical)	
			Heavy metals	
			pH	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	
			Assay: Sodium chloride (Chemical)	
			Sterility	
330	387	Ascorbic Acid Tablets IP 500 mg	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Assay: (Chemical)	
			Ascorbic Acid	
			Identification of colour	
331	388	Calcium Gluconate Injection IP 10% (IV use)	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: Calcium gluconate (blank Titrationl)	
			Sterility	
332	390	Ferrous Sulphate and Folic Acid Tablets IP Each film coated Tablets Containing Dried Ferrous Sulphate IP- equivalent to 100mg Elemental Iron and Folic Acid IP 0.5mg	Description	
			Identification of:	
			Folic acid (by HPLC)	
			Ferrous sulphate	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Uniformity of weight	
			Ferric iron	
			Uniformity of content:	
			Folic acid (by HPLC)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Folic acid (by HPLC)	
			Dried ferrous sulphate calculated as elemental iron	
			Identification of colour	
333	391	Ferrous Sulphate with Folic Acid Tablets (Paediatric) IP Each film coated Tablets Containing Dried Ferrous Sulphate IP- equivalent to 20mg Elemental Iron and Folic Acid IP 100 mcg.	Description	
			Identification of:	
			Folic acid (by HPLC)	
			Ferrous sulphate	
			Average weight	
			Uniformity of weight	
			Ferric iron	
			Uniformity of content: Folic acid (by HPLC)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Folic acid (by HPLC)	
			Dried ferrous sulphate calculated as elemental iron	
			Identification of colour	
334	392	Folic Acid Tablets IP 5 mg	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			Average weight	
			Disintegration time	
			Uniformity of content (by HPLC)	
			Hydrolysis products (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
335	393	Multivitamin Drops Each ml contains Vit-A -3000 IU, Vit-D3-300 IU, Vit-B1 -1mg, Riboflavine Phosphate Sodium -2mg, D-Panthenol -2.5mg, Niacinamide -10mg, Pyridoxine HCL-1mg, Cyanocobalamin 1mcg, Lysine HCL 10mg	Description	
			pH	
			Contents of Packaged Dosage Forms	
			Assay:	
			Vitamin A (by UV)	
			Vitamin D3 (by HPLC)	
			Thiamine hydrochloride (by UV)	
			Riboflavin sodium phosphate (by UV)	
			Pyridoxine hydrochloride (by UV)	
			Cyanocobalamin (by Microbiological assay)	
			D-Panthenol (by UV)	
			Niacinamide (by UV)	
			L-Lysine hydrochloride (by UV)	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
336	394	Multivitamin Tablets NFI Formula Sugar coated. Vit A 2500 IU, Vit B1-2mg, Vit-B6-0.5mg, Vit-C-50mg, Calcium Pantothenate-1mg, Vit-D3-200IU, Vit-B2 2 mg, Niacinamide-25mg, Folic Acid-0.2 mg	Description	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Disintegration Time	
			Assay:	
			Vitamin A (by UV)	
			Vitamin B1 (by UV)	
			Vitamin B6 (by UV)	
			Vitamin C	
			Calcium Pantothenate (by HPLC)	
			Vitamin D3 (by HPLC)	
			Vitamin B2 (by UV)	
			Niacinamide 25 mg (by UV)	
			Folic acid 0.2 mg (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification of colour	
337	395	Vitamin B Complex Injection NFI	Description	
			pH	
			Particulate matter	
			Extractable volume	
			Assay:	
			Thiamine hydrochloride (by UV)	
			Riboflavine sodium phosphate calculated as Riboflavine (by UV)	
			Pyridoxine hydrochloride (by UV)	
			Nicotinamide (by UV)	
			D-Panthenol (by UV)	
			Sterility	
338	397	Vitamin–B complex Tablets NFI (prophylactic) B1- 2mg, B2- 2mg, B6- 0.5mg, Niacinamide 25mg, Calcium pantothenate 1mg (With appropriate overages)	Description	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Disintegration Time	
			Assay:	
			Vitamin B1 (by UV)	
			Vitamin B2 (by UV)	
			Vitamin B6 (by UV)	
			Niacinamide (by UV)	
			Calcium pantothenate (by HPLC)	
339	398	Black Disinfectant Fluid (Phenyl) (As per Schedule "O" Grade – III	Description	
			Stability after dilution	
			Germicidal Value (Rideal walker Coefficient)	
			Weight per ml	
340	399	Concentrated Solution for Haemodialysis B.P Acetate concentrate in 10 Litre Cans.	Description	
			Identification for	
			Potassium	
			Calcium	
			Sodium	
			Chlorides	
			Lactates	
			Carbonates and hydrogen carbonates	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Acetates	
			Magnesium	
			Glucose	
			Tests for	
			Appearance of solution	
			Aluminium	
			Extractable volume	
			Microbial contamination: TAMC.	
			Bacterial endotoxins	
			Assay for:	
			Sodium by AAS & AES	
			Potassium by AAS	
			Calcium by AAS	
			Magnesium by AAS	
			Total chloride by titration	
			Acetate by potentiometric titration	
			Lactate by potentiometric titration	
			Sodium hydrogen carbonate by potentiometric titration	
			Reducing sugars by titration	
341	401	Peritonial Dialysis Solution IP	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Chloride	
			Sodium Salts	
			Potassium Salt	
			Calcium Salts	
			Identification C (Chemical)	
			Identification D (Chemical)	
			Identification E (Chemical)	
			Lactate and Bicarbonate (HPLC)	
			Appearance of solution	
			5-Hydroxymethyl furfural and Related substances (by UV)	
			Aluminium (Fluorescence)	
			Particulate Contamination (Particle analyzer)	
			PH	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay:	
			Sodium (By FP)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Potassium(By FP)	
			Calcium(By FP)	
			Magnesium (by Titration)	
			Total Chloride(by Titration)	
			Acetate (by HPLC)	
			Lactate(by HPLC)	
			Sodium bicarbonate (by Titration)	
			Lactate and Bicarbonate (HPLC)	
			Dextrose (Chemical)	
			Sterility	
342	402	Sodium Bicarbonate Injection IP 7.5% w/v	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			PH	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (Chemical)	
			Sterility	
343	404	Water for Injection I.P.	Description	
			Appearance of solution	
			Acidity or alkalinity	
			Ammonium	
			Calcium and magnesium	
			Heavy metals	
			Chlorides	
			Nitrates	
			Sulphates	
			Oxidisable substances	
			Residue on evaporation	
			Particulate contamination	
			Bacterial enditoxins	
			Extractable volume	
			Sterility	
344	405	Polygeline 3.5% Solution with electrolytes for I.V. Infusion	Description	
			Identification	
			Nitrogen (Chemically)	
			Total Sodium (Chemically)	
			Total Potassium (Chemically)	
			Calcium (Chemically)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Total Chloride (Chemically)	
			Nominal Volume	
			Extractable Volume	
			Ph	
			Particulate matter	
			Bacterial Endotoxins	
			Assay	
			Nitrogen (Chemically)	
			Total Sodium (AAS)	
			Total Potassium (AAS)	
			Calcium (AAS)	
			Total Chloride (Chemically)	
			Sterility	
345	406	Factor – IX Concentrate (Purified) 500-600 I.U.(Human Coagulation Factor IX)	NQ	
346	407	Anti-Inhibitor coagulation Complex (Human Plasma Protein with a Factor VIII Inhibitor Bypassing Activity of 500 IU per Vial)	NQ	
347	408	Rabies Antiserum IP (Equine) 300 units per ml [contains equine anti-rabies immunoglobulin fragments](I.M./SC use)	NQ	
348	409	Vitamin A Paediatric oral solution IP Vitamin A concentrate oil IP Each ml contains vitamin A 100000IU	Description	
			Identification B (by Chemical)	
			Identification C (by HPLC)	
			Identification D (by UV)	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
349	410	Labetalol Tablets IP 100mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			Average weight	
			Diasterioisomer ratio: BY GC	
			Related substances (by TLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration time	
			Uniformity Of weight	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
350	411	Labetalol Hydrochloride Injection IP 20mg/4ml	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			pH	
			Free carboxylic acid and other related substances (by TLC)	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
351	412	Ampicillin Capsules IP 500 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
352	413	Nitrofurantoin Tablets IP 100mg	Description	
			Identification (by UV)	
			Average weight	
			Uniformity of weight	
			Related substances (by TLC)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
353	414	Hyoscine Butylbromide Tablets IP 10mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Average weight	
			Hyoscine (by HPLC)	
			Related substances (by TLC)	
			Uniformity of content (by HPLC)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification of colour	
354	415	Drotaverine Tablets IP 40 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
355	416	Hydroxyethyl Starch (130/0.4) 6% w/v with Sodium Chloride 0.9% w/v Intravenous Infusion	Description	
			Identification	
			Total Sodium	
			Total Potassium	
			Total Magnesium	
			Total Chloride	
			Total Acetate	
			Poly starch	
			Ph	
			Theoritical Osmolarity	
			Titrable Acidity	
			Content of Poly (0-2-Hydroxy ethyl starch) Starch	
			Particulate Contamination	
			Extractable Volume	
			Nominal Volume	
			Assay	
			Total Sodium (By AAS)	
			Total Potassium (By AAS)	
			Total Magnesium (By AAS)	
			Total Chloride (Chemically)	
			Total Acetate (HPLC)	
			Sterility	
356	417	Cloxacillin sodium Injection IP 500 mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			pH	
			Bacterial endotoxins	
			Average net content	
			Uniformity of weight	
			Water	
			Clarity of solution test a and b	
			Particulate matter	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by HPLC)	
			Sterility	
357	418	Betamethasone Sodium Phosphate Injection IP 4mg/ml	Description	
			Identification A (by TLC)	
			Identification B (by UV)	
			pH	
			bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
358	419	Vecuronium Bromide for Injection 4 mg (Freeze Dried)	Description	
			Identification A (by HPLC)	
			pH	
			Light absorption (by UV)	
			Water	
			Bacterial Endotoxins	
			Average net content	
			Uniformity of weight	
			Related substances (by HPLC)	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
359	420	Phenobarbitone Injection IP 200mg/ml	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			pH	
			Weight per ml	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: Phenobarbital sodium (Chemical)	
			Sterility	
360	421	Flurbiprofen Sodium Ophthalmic Solution USP 0.03% w/v / Flurbiprofen Eye Drops IP 0.03% w/v	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			pH	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			2-(biphenyl-4-yl) propionic acid (by HPLC)	
			Particulate Matter	
			Nominal Volume	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
361	423	Hyaluronidase Injection IP Each vial contains Hyaluronidase IP 1500 I.U.	Description	
			Identification A (by Chemical)	
			Identification B (Performed on animals)	
			pH	
			Average Weight	
			Uniformity Of weight	
			Clarity of solution test a and b	
			Appearance of solution	
			Particulate matter	
			Bacterial endotoxins	
			Assay: Phenobarbital sodium (by UV)	
			Sterility	
362	424	Lidocaine Hydrochloride Topical Solution USP 4%	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Organic impurities: (by HPLC)	
			pH	
			Uniformity of Volume	
			Average Volume	
			Net content	
			Assay: (by HPLC)	
363	425	Fluconazole Eye Drops 0.3%	Description	
			Identification (by HPLC)	
			pH	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Sterility	
364	427	Cephalexin Oral Suspension IP (Cephalexin Dry Syrup IP) 125 mg/ 5 ml	Description	
			Identification A (by HPLC)	
			Identification B (Chemical)	
			Contents of Packaged Dosage Forms	
			Weight per ml	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by HPLC)	
			Stability of suspension (by HPLC)	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
365	428	Ofloxacin oral Suspension IP 50mg/ 5ml	Description	
			Identification (by HPLC)	
			Contents of Packaged Dosage Forms	
			Weight per ml	
			Assay: (by HPLC)	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
366	430	Tinidazole Tablets IP 300 mg (Film Coated)	Description	
			Identification A (by UV)	
			Identification B (by Chemical)	
			Identification C: Melting Point	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
367	431	Tinidazole Tablets IP 500 mg (Film Coated)	Description	
			Identification A (by UV)	
			Identification B (by Chemical)	
			Identification C: Melting Point	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
368	432	Salbutamol Syrup IP 2mg/ 5ml	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			pH	
			2-tert-butylamino-1-(4-hydroxy-3-methylphenyl) ethanol (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
369	433	Ranitidine Tablets IP 300 mg (Film coated)	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
370	436	Indomethacin Capsules IP 25 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (Chemical)	
			Average net content	
			Uniformity of weight	
			Related substances (by TLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
371	437	Diclofenac Prolonged Release Tablets IP 100mg	Description	
			Identification (by IR)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			1st time point	
			2nd time point	
			3rd time point	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification of colour	
372	438	Dicyclomine Hydrochloride and Activated Dimethicone suspension. Each ml contains: Dicyclomine Hydrochloride 10mg, Activated Dimethicone 40mg	Description	
			Identification of: Polydimethylsiloxane (by IR)	
			Dicyclomine hydrochloride	
			pH	
			Contents of Packaged Dosage Forms	
			Assay:	
			Dicyclomine Hydrochloride	
			Polydimethylsiloxane (by IR)	
			Microbiological Examination	
			Total Aerobic count	
			Total Fungal count	
			E. coli	
373	439A	Dicyclomine and Paracetamol Tablets (Dicyclomine Hydrochloride 20 mg + Paracetamol 325 mg Tablets	Description	
			Identification of:	
			Dicyclomine hydrochloride	
			Paracetamol	
			Average weight	
			Uniformity of weight	
			Uniformity of content of Dicyclomine HCL (if applicable)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Dicyclomine Hydrochloride (BY UV)	
			Paracetamol 500 mg (by UV)	
374	440	Dextromethorphan Hydrobromide Syrup IP 13.5mg / 5ml	Description	
			Identification A (by optical rotation)	
			Identification B (Chemical)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
375	441	Calcium & Vitamin D3 Suspension (Each 5 ml contains Calcium Carbonate equivalent to elemental Calcium 250 mg, Vitamin D3 - 125 IU)	Description	
			Identification of:	
			Calcium and carbonate	
			Vitamin D3 (by HPLC)	
			pH	
			Contents of Packaged Dosage Forms	
			Weight per ml	
			Assay:	
			Vitamin D3 125 IU (by HPLC)	
			Calcium	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
376	442	Saline Nasal Solution (Drops / Spray) (Sodium chloride 0.65%)	Description	
			Identification of Sodium	
			Identification of Chloride	
			pH	
			Contents of Packaged Dosage Forms	
			Assay: (by Titration)	
377	443	Clotrimazole mouth paint (Clotrimazole 1% w/v)	Description	
			Identification of Clotrimazole (by HPLC)	
			Ph	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
378	444	Aspirin Gastro resistant Tablets IP Each enteric coated Tablets contains Acetyl Salicylic Acid 75 mg	Description	
			Identification (Chemical)	
			Average weight	
			Dissolution A:	
			At acid stage (by UV)	
			Dissolution B:	
			At buffer stage (by UV)	
			Uniformity of weight	
			Salicylic acid (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by HPLC)	
			Identification of colours (by TLC)	
379	445	Beclomethasone, Neomycin, and Clotrimazole Cream (Beclomethasone dipropionate 0.025%, Neomycin sulphate 0.5% Clotrimazole1%)	Description	
			Identification of:	
			Neomycin sulphate (by TLC)	
			Beclomethasone dipropionate (by HPLC)	
			Clotrimazole (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Neomycin sulphate (by Microbiological assay)	
			Beclomethasone dipropionate (by HPLC)	
			Clotrimazole (by HPLC)	
380	446	Gamma Benzene Hexachloride Lotion 1% (Lindane lotion USP) (Lindane Application BP)	Description	
			Identification (by Chemical)	
			Ph	
			Contents of Packaged Dosage Forms	
			Assay: (by GC)	
381	447	Chlorhexidine Gluconate Solution 5%	Description	
			Identification	
			PH	
			Weigh Per ml	
			Contents of Packaged Dosage Forms	
			Assay: (by titration)	
			Identification of colours (by TLC)	
382	448	Iron and Folic Acid Suspension.	Description	
			Identification of:	
			Ferrous Fumerate	
			Folic acid	
			Weight per ml	
			pH	
			Nominal Volume	
			Contents of Packaged Dosage Forms	
			Assay:	
			Folic acid	
			Ferrous Fumerate as elemental iron	
			Identification of colour	
			Microbial Contamination	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Total aerobic viable count	
			Total fungal count	
			E. coli	
383	449	Surgical Spirit IP	Description	
			Identification A	
			Identification B	
			Weight/ml	
			Net content	
			Assay:	
			For Methyl Salisylate (by UV)	
			For Diethyl Phthalate (by UV)	
384	450	Povidone Iodine Solution IP 5%	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Contents of Packaged Dosage Forms	
			pH	
			Ethanol (if present)	
			Assay: Povidone iodine	
385	451	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			1st time point	
			2nd time point	
			3rd time point	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
386	452	Glipizide and Metformin Hydrochloride Tablets USP (Glipizide 5mg, Metformin Hydrochloride 500 mg)	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Identification C (by HPLC)	
			Average weight	
			Uniformity of Weight	
			[Content uniformity]: Glipizide (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution of:	
			Glipizide (by HPLC)	
			Metformin hydrochloride (by HPLC)	
			Organic impurities: (by HPLC)	
			Glipizide (by HPLC)	
			Metformin hydrochloride (by HPLC)	
			Assay:	
			Glipizide (by HPLC)	
			Metformin hydrochloride (by HPLC)	
387	453	Glibenclamide and Metformin Hydrochloride (SR) Tablets [Glibenclamide 5mg, Metformin hydrochloride 500 mg (Sustained Release)]	Description	
			Identification of:	
			Glibenclamide (by HPLC)	
			Metformin hydrochloride (by UV)	
			Average weight	
			Uniformity of weight	
			Uniformity of content: Glibenclamide (by HPLC)	
			Dissolution: Glibenclamide (HPLC)	
			Metformin hydrochloride (by UV)	
			1st time point	
			2nd time point	
			3rd time point	
			Related Substances (By HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Metformin hydrochloride (by HPLC)	
			Glibenclamide (by HPLC)	
			Identification of colour	
388	454	Metformin Hydrochloride (Sustained Release) and Glimperiride Tablets IP {Metformin hydrochloride (Sustained Release) 500 mg, Glimipiride 1 mg}	Description	
			Identification (HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution of Metformin hydrochloride (by UV)	
			1st time point	
			2nd time point	
			3rd time point	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Glimepiride (by HPLC)	
			Uniformity of content:	
			Glimepiride (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Glimepiride (by HPLC)	
			Metformin hydrochloride (by UV)	
			Identification of colour	
389	455	Metformin Hydrochloride (Sustained Release) and Glimperiride Tablets IP {Metformin hydrochloride (Sustained Release) 500 mg, Glimipiride 2 mg}	Description	
			Identification (HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution of Metformin hydrochloride (by UV)	
			1st time point	
			2nd time point	
			3rd time point	
			Glimepiride (by HPLC)	
			Uniformity of content:	
			Glimepiride (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Glimepiride (by HPLC)	
			Metformin hydrochloride (by UV)	
			Identification of colour	
390	456	Glimperiride, Pioglitazone and Metformin Hydrochloride (Sustained Release) Tablets Each Tablets contains Glimepiride 2mg, Pioglitazone 15mg, Metformin Hydrochloride(Sustained release) 500 mg	Description	
			Identification of: Metformin hydrochloride (by UV)	
			Glimepiride (by HPLC)	
			Pioglitazone hydrochloride (by HPLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of content:	
			Glimepiride (by HPLC)	
			Pioglitazone hydrochloride (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution of Metformin hydrochloride (by UV)	
			1st time point	
			2nd time point	
			3rd time point	
			Contents of Packaged Dosage Forms	
			Assay:	
			Glimepiride (by HPLC)	
			Metformin hydrochloride (by UV)	
			Pioglitazone (by HPLC)	
			Identification of colour	
391	457	Amlodipine and Enalapril Maleate Tablets (Amlodipine Besilate equivalent to Amlodipine 5mg, Enalapril maleate 5mg)	Description	
			Identification of:	
			Amlodipine besylete (by HPLC)	
			Enalapril maleate (by HPLC)	
			Average weight	
			Uniformity of content :	
			Amlodipine besylete (by HPLC)	
			Enalapril maleate (by HPLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Amlodipine besylete (by HPLC)	
			Enalapril maleate (by HPLC)	
392	458	Losarton Potassium & Amlodipine Tablets IP (Losarton Potassium 50 mg, Amlodipine Besilate eq. to Amlopdipine 5mg)	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of content: Amlodipine (by HPLC)	
			Dissolution (by HPLC):	
			Losartan potassium	
			Amlodipine	
			Contents of Packaged Dosage Forms	
			Assay:	
			Amlodipine (by HPLC)	
			Losartan potassium (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
393	459	Losarton Potassium & Hydrochlorothiazide Tablets IP (Losarton Potassium 50 mg, Hydrochlorothiazide Tablets 12.5mg)	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of content: Hydrochlorothiazide (by HPLC) (If applicable)	
			Dissolution (by HPLC)	
			Losartan potassium	
			Hydrochlorothiazide	
			Contents of Packaged Dosage Forms	
			Assay:	
			Hydrochlorothiazide (by HPLC)	
			Losartan potassium (by HPLC)	
			Identification of colours	
394	460	Amlodipine and Lisinopril Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Lisinopril eq. to lisinopril (anhydrous) 5mg]	Description	
			Identification of:	
			Amlodipine (by HPLC)	
			Lisinopril (by HPLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of content:	
			Amlodipine (by HPLC)	
			Lisinopril (by HPLC)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Amlodipine (by HPLC)	
			Lisinopril (by HPLC)	
395	461	Amlodipine and Atenolol Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Atenolol 50mg]	Description	
			Identification of:	
			Amlodipine (by HPLC)	
			Atenolol (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of content:	
			Amlodipine (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Amlodipine (by HPLC)	
			Atenolol (by HPLC)	
396	462	Atenolol Tablets IP 25 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by UV)	
397	463	Enalapril Maleate Tablets IP 10 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
398	464	Hydrochlorthiazide Tablets IP 25 mg	Description	
			Identification (by TLC)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
399	465	Lisinopril Tablets IP 10 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
400	466	Lisinopril Tablets IP 2.5 mg	Description	
			Identification (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
401	467	Losartan Tablets IP 25 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
402	468	Piperacillin and Tazobactum for Injection USP 4 gm + 500 mg	Description	
			Identification (by HPLC)	
			pH	
			Related substances (by HPLC)	
			Water	
			Bacterial endotoxins	
			Average net content	
			Uniformity of weight	
			Clarity of solution test a and b	
			Particulate matter	
			Assay:	
			Piperacillin (by HPLC)	
			Tazobactum (by HPLC)	
			Sterility	
403	469	Prednisolone Tablets IP 10 mg	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Average weight	
			Related substances (by HPLC)	
			Uniformity of content (by UV)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
404	470	Prednisolone Tablets 20 mg	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Average weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Related substances (by HPLC)	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
405	471	Torsemide Injection 10 mg/ml	Description	
			Identification (by UV)	
			pH	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
406	472	Zinc Sulphate Dispersible Tablets IP Elemental Zinc 10 mg	Description	
			Identification A (by Chemical)	
			Identification B (by Chemical)	
			Average weight	
			Uniformity of content	
			Uniformity of dispersion	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: Elemental Zinc	
407	473	Amoxycillin Oral Suspension IP (Dry Syrup) 125 mg/5 ml	Description	
			Identification (by HPLC)	
			pH	
			Contents of Packaged Dosage Forms	
			Weight per ml	
			Assay: (by HPLC)	
			Stability of suspension (by HPLC)	
			Microbial Contamination	
			Total aerobic viable count	
			Total fungal count	
			E. coli	
408	474	Carbamazepine Oral Suspension USP 100 mg/5ml	Description	
			Identification A (by IR)	
			Deliverable volume	
			Uniformity of dosage units:	
			Assay: (by HPLC)	
			Microbial enumeration tests and tests for specified microorganisms	
			Total bacterial count	
			Salmonella	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			E. coli	
409	475	Cefpodoxime Dispersible Tablets 50 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Uniformity of dispersion	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
410	476	Cephalexin Tablets 125 mg (Dispersible Tablets)	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Uniformity of dispersion	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
411	477	Ibuprofen Oral Suspension BP/USP 100 mg/ 5 ml	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			4-Isobutylacetophenone (by HPLC)	
			Assay: (by HPLC)	
			Uniformity of mass	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
412	478	Metoclopramide Hydrochloride Syrup IP 5 mg/ 5ml	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Identification of colour	
			Assay: (by UV)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			E. coli	
413	479	Sodium Valproate Oral Solution IP 200 mg / 5 ml	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Related substances (by GC)	
			Weight/ml	
			Contents of Packaged Dosage Forms	
			Identification of colour	
			Assay: Sodium valproate **(Chemical)**	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
414	480	Diphtheria Antitoxin 10000 IU	NQ	
415	481	Meropenem Injection IP 1 gm	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			pH	
			Related Substances (by HPLC)	
			Content of Sodium (by FP/AAS)	
			Bacterial endotoxins	
			Loss on drying	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
416	482	Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 300 mg Iodine/ml.	Description	
			Identification (by HPLC)	
			Organic impurities (by HPLC)	
			Bacterial endotixins	
			pH	
			Particulate matter (by Liquid particle size analyzer)	
			Free Iodide	
			Sterility	
			Extractable volume	
			Assay	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
417	483	Diclofenac Sodium and Paracetamol Tablets Diclofenac Sodium 50 mg + Paracetamol 325 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution by HPLC:	
			Diclofenac sodium	
			Paracetamol	
			4-Aminophenol (by HPLC)	
			Uniformity of Content of Diclofenac sodium (by HPLC) (if applicable)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Diclofenac sodium (by HPLC)	
			Paracetamol (by HPLC)	
418	484	Timolol Eye Drops IP 0.5% w/v	Description	
			Identification A (by IR)	
			Identification B (by Chemical)	
			pH	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Sterility	
419	485	Homatropine Eye Drops IP 2 %	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Sterility	
420	486	Travoprost Eye Drops IP 0.004%	Description	
			Identification A (by HPLC)	
			Identification B (by TLC)	
			pH	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Sterility	
421	487	Brimonidine Tartrate and Timolol Maleate Eye Drops 0.15% + 0.5%	Description	
			Identification of:	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Brimonidine tartrate	
			Timolol Maleate	
			pH	
			Contents of Packaged Dosage Forms	
			Particulate Matter	
			Assay:	
			Brimonidine tartrate	
			Timolol maleate	
			Sterility	
422	488	Iron Sucrose Injection USP/BP 20mg/ml (For IV Use) Each ml contain: Ferric hydroxide in complex with Sucrose equivalent to elemental Iron 20 mg	Description	
			Identification A	
			Iron (Chemical)	
			Identification B (By HPLC)	
			Molecular Weight Determination (by HPLC)	
			Limit of Iron	
			Turbidity	
			Absence of low Molecular weight Iron Fe^{II} and Fe^{III} Complexes	
			Alkalinity	
			Osmolality and Osmolarity	
			Specific Gravity	
			Content of Chloride	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay:	
			Iron (AAS)	
			Surose (HPLC)	
			Sterility	
423	491	Sevoflurane	Description	
			Identification (by IR)	
			Limits of Fluoride	
			Limit of Non Volatile Residue	
			Organic Impurities (By GC)	
			Refractive Index	
			Water	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Acidity or Alkalinity	
			Nominal Volume	
			Assay: (by GC)	
424	492	Aceclofenac and Paracetamol Tablets Aceclofenac 100 mg and Paracetamol 325 mg	Description	
			Identification of:	
			Aceclofenac	
			Paracetamol	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Aceclofenac (by HPLC)	
			Paracetamol (by HPLC)	
425	493	Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5%	Description	
			Identification of:	
			Diclofenac (by HPLC)	
			Linseed oil (by GC)	
			Menthol (by GC)	
			Methyl salicylate (by GC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Diclofenac (by HPLC)	
			Linseed oil (by GC)	
			Menthol (by GC)	
			Methyl salicylate (by GC)	
426	495	Etoricoxib Tablets IP 120 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by UV)	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
427	496	Mefenamic Acid Tablets BP 500 mg	Description	
			Identification (by IR)	
			Average weight	
			Uniformity of mass	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Related substances (by TLC)	
			2,3-Dimethylaniline (by TLC)	
			Assay: Mefenamic acid	
428	497	Anticold Syrup Each 5 ml contains Phenylephrine Hydrochloride 2.5mg , Chlorpheniramine maleate 1 mg, and Paracetamol 125 mg	Description	
			Identification of:	
			Paracetamol (by UV)	
			Phenyleprine hydrochloride (by UV	
			Chlorpheniramine maleate (by UV)	
			pH	
			Contents of Packaged Dosage Forms	
			Assay:	
			Paracetamol (by UV)	
			Phenylephrine hydrochloride (by UV)	
			Chlorpheniramine maleate (by UV)	
			Identification of colour	
			Microbiological Examination	
			Total Aerobic count	
			Total Fungal count	
			E. coli	
429	498	Cetirizine, Phenylephrine & Paracetamol Tablets Cetirizine 5 mg, Phenylephrine 10 mg & Paracetamol 325 mg	Description	
			Identification of:	
			Cetirizine hydrochloride (by HPLC)	
			Phenylephrine hydrochloride (by UV)	
			Paraceatmol (by UV)	
			Average weight	
			Uniformity of weight	
			Uniformity of content:	
			Cetirizine hydrochloride (by HPLC)	
			Phenypehrine hydrochloride (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Cetirizine hydrochloride (by HPLC)	
			Phenylephrine hydrochloride (by UV)	
			Paracetamol (by UV)	
430	499	Cetirizine Syrup IP 5 mg/ 5ml	Description	
			Identification (by HPLC)	
			Weight per ml	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			pH	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
			Microbiological Examination	
			Total Aerobic count	
			Total Fungal count	
			E. coli	
431	500	Acetylcystine Solution USP /BP (Injection) 200 mg/ ml	Description	
			Identification (by IR)	
			pH	
			Related Substances (by HPLC)	
			Hydrogen sulfide	
			Bacterial endotoxins	
			Extractable volume	
			Particulate Matter	
			Assay: (by titration)	
			Sterility	
432	502	Acyclovir Intravenous Infusion IP 250 mg	Description	
			Identification A (by UV)	
			Identification B (by TLC)	
			Identification C (Chemical)	
			pH	
			Appearance of Solution	
			Average net content	
			Uniformity of weight	
			Guanine (by TLC)	
			Related Substances (by TLC)	
			Bacterial endotoxins	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
433	503	Acyclovir Intravenous Infusion IP 500 mg	Description	
			Identification A (by UV)	
			Identification B (by TLC)	
			Identification C	
			pH	
			Appearance of Solution	
			Average net content	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight	
			Guanine (by TLC)	
			Related Substances (by TLC)	
			Bacterial endotoxins	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
434	504	Amikacin Injection IP 250 mg	Description	
			Identification A by TLC	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: Microbiological assay	
			Sterility	
435	505	Amoxicillin and Potassium Clavulante Injection IP 600 mg	Description	
			Identification (by TLC)	
			Identification (by HPLC)	
			pH	
			Bacterial Endotoxins	
			Water	
			Average net content	
			Uniformity of weight	
			Clarity of solution test a and b	
			Particulate matter	
			Assay:	
			Amoxycillin (by HPLC)	
			Clavulanic acid (by HPLC)	
			Sterility	
436	506	Amoxicillin and Potassium Clavulante Injection IP 1.2 g	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			pH	
			Bacterial Endotoxins	
			Water	
			Average net content	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight	
			Clarity of solution test a and b	
			Particulate matter	
			Assay:	
			Amoxycillin (by HPLC)	
			Clavulanic acid (by HPLC)	
			Sterility	
437	507	Amoxicillin and Potassium Clavulante Oral Suspension IP 200 mg + 28.5 mg per 5 ml	Description	
			Identification (by HPLC)	
			pH	
			Water	
			Contents of Packaged Dosage Forms	
			Assay:	
			Amoxycillin (by HPLC)	
			Clavulanic acid (by HPLC)	
			Stability of suspension on 7th day	
			Amoxycillin (by HPLC)	
			Clavulanic acid (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
438	508A	Artesunate Injection 60 mg (I.M./I.V. Use) Each Combo Pack contains Artesunate Injection 60 mg Vial, Sodium Bicarbonate Injection IP 5% w/v (1 ml ampoule), Sodium chloride Injection IP 0.9% w/v (5 ml ampoule)	**Artesunate Injection IP**	
			Description	
			Identification A (by IR)	
			Average net content	
			Uniformity of weight	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Water	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
			Sodium Bicarbonate Injection IP	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Description	
			Identification A	
			Identification B	
			pH	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: Sodium bicarbonate	
			Sterility	
			Sodium chloride Injection IP	
			Description	
			Identification	
			Heavy metals	
			pH	
			Extractable volume	
			Bacterial endotoxins	
			Particle Matter (Particle Counter)	
			Assay: Sodium chloride	
			Sterility	
439	509	Aztreonam Injection USP 500 mg	Description	
			Identification (HPLC)	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: by HPLC	
			Sterility	
440	510	Cefepime Injection IP 500 mg	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			PH	
			N-methylPyrolidine (HPLC)	
			Average net content	
			Uniformity of weight	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Water	
			Clarity of solution test a and b	
			Particulate matter	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by HPLC)	
			Sterility	
441	511	Cefixime Oral Suspension IP 25 mg/ ml (Paediatric Drops)	Description	
			Identification (by HPLC)	
			pH	
			Contents of Packaged Dosage Forms	
			Water	
			Weight per ml	
			Assay: (by HPLC)	
			Stability of suspension (by HPLC)	
			Identification of colour	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
442	512	Cefuroxime Axetil Tablets IP 250 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
443	513	Clindamycin Capsules IP 150 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Disintegration time	
			Water	
			Contents of Packaged Dosage Forms	
			Related substances (by HPLC)	
			Assay: (by HPLC)	
444	514	Clindamycin Capsules IP 300 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration time	
			Water	
			Contents of Packaged Dosage Forms	
			Related substances (by HPLC)	
			Assay: (by HPLC)	
445	515	Levofloxacin Tablets IP 250 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colours	
446	516	Linezolid Tablets IP 600 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
447	517	Linezolid Injection 200 mg/ 100 ml	Description	
			Identification	
			Linezolid (by HPLC)	
			Dextrose (Chemical)	
			pH	
			Particulate matter (by liquid particle counter)	
			Extractable volume	
			Sterility	
			Assay:	
			Linezolid (by HPLC)	
			Dextrose (Chemical)	
448	518	Mefloquine Tablets IP 250 mg	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
449	519	Metronidazole & Norfloxacin suspension 100 + 100 mg per 5 ml	Description	
			Identification of:	
			Metronidazole (by HPLC)	
			Norfloxain (by HPLC)	
			pH	
			Contents of Packaged Dosage Forms	
			Weight per ml	
			Assay:	
			Metronidazole (by HPLC)	
			Norfloxacin 100 mg (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
450	520	Ofloxacin and Ornidazole Tablets (Ofloxacin 200 mg and Ornidazole 500 mg)	Description	
			Identification (BY HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution	
			Ofloxacin (by HPLC)	
			Ornidazole (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Ofloxacin (by HPLC)	
			Ornidazole (by HPLC)	
451	521	Ofloxacin Infusion IP 200mg/ 100 ml (in NaCl Injection)	Description	
			Identification A (by HPLC)	
			pH	
			Bacterial endotoxins	
			Particulate matter (by particle counter)	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
			Additional test	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Sodium chloride content (by titration)	
452	523	Vancomycin for Intravenous Infusion IP 500 mg	Description	
			Identification A (by HPLC)	
			Identification B (by Chemical)	
			pH	
			Appearance of solution	
			Average net content	
			Uniformity of weight	
			Water	
			Related Substances (by HPLC)	
			Vancomycin B (by HPLC)	
			Bacterial endotoxins	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by Microbiological assay)	
			Sterility	
453	524	Vancomycin for Intravenous Infusion IP 1 gm	Description	
			Identification A (by HPLC)	
			Identification B	
			pH	
			Appearance of solution	
			Average net content	
			Uniformity of weight	
			Water	
			Related Substances (by HPLC)	
			Vancomycin B (by HPLC)	
			Bacterial endotoxins	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by Microbiological assay)	
			Sterility	
454	525	Alpha Interferon Injection (Interferon Alpha-2 concentrated Solution IP) 3 million unit	NQ	
455	526	Carboplatin Injection 150 mg	Description	
			Identification A by TLC	
			Identification B by HPLC	
			Acidity:pH	
			Limit of Cyclobutane-1,1-Dicarboxylic acid by HPLC	
			Bacterial Endotoxins	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Sterlity	
			Extractable volume	
			Particulate Matter	
			Assay by HPLC	
456	527	Carboplatin Injection 450 mg	Description	
			Identification A by TLC	
			Identification B by HPLC	
			Acidity:pH	
			Limit of Cyclobutane-1,1-Dicarboxylic acid by HPLC	
			Bacterial Endotoxins	
			Sterlity	
			Extractable volume	
			Particulate Matter	
			Assay by HPLC	
457	528	Cisplatin Injection IP 10 mg/ 10 ml	Description	
			Identification A by UV	
			Identification B by HPLC	
			pH	
			Tri Chloroammineplatinate by HPLC	
			Transplatine by HPLC	
			Bacterial Endotoxins	
			Sterlity	
			Extractable volume	
			Particulate Matter	
			Assay by HPLC	
458	529	Dacarbazine Injection 500 mg USP/ BP	Description	
			Identification A by UV	
			Identification B by HPLC	
			pH	
			5-Aminoimidazole-4-carboxamide hydrochloride by HPLC	
			Related Substances (by HPLC)	
			Bacterial Endotoxins	
			Sterlity	
			Particulate Matter	
			Assay by UV	
459	530	Filgrastim Injection (Granulocyte Colony Stimulation Factor) 300 mcg [SC/IV use]	NQ	
460	531	Gemcitabine for Injection 200 mg	Description	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Clarity of solution	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
461	532	Gemcitabine for Injection 1 gm	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			pH	
			Related substances (by HPLC)	
			Bacterial endotoxins	
			Clarity of solution	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
462	533	Ifosfamide Injection USP/ BP 1 gm	Description	
			Identification (by IR)	
			Appearance of solution	
			Average net content	
			Uniformity of weight	
			pH	
			Related substances (by TLC)	
			Water	
			Bacterial endotoxins	
			Clarity of solution test a and b	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
463	534	Imatinib Tablets 400 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by HPLC)	
464	536	Methotrexate Tablets IP 10 mg	Description	
			Identification (by UV)	
			Average weight	
			Uniformity of Content (HPLC)	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
465	537	Mitomycine Injection IP 10 mg / Mitomycine for Injection USP 10 mg	Description	
			Identification (by TLC)	
			Average net content	
			Uniformity of weight	
			pH	
			Water	
			Bacterial endotoxins	
			Clarity of solution	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
466	538	Oxaliplatin Injection USP 50 mg	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Oxalic Acid (HPLC)	
			Related substances (HPLC)	
			Average net content	
			Uniformity of weight	
			pH	
			Bacterial endotoxins	
			Clarity of solution	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
467	540	Bromocriptine Tablets IP 2.5 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Identification C (by TLC)	
			Average weight	
			Uniformity of content (by UV)	
			Related substances (by TLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
468	541	Betahistine Tablets IP 8 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
469	542	Betahistine Tablets IP 16 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of Weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
470	543	Cinnarizine Tablets IP 25 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
471	544	Cinnarizine Tablets IP 75 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
472	545	Tranexamic Acid Tablets IP/BP 500 mg	Description	
			Identification A (by IR)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification B (by Chemical)	
			Identification C (by melting point)	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: Tranexamic acid (by blank titration)	
473	546	Warfarin Sodium Tablets IP 5 mg	Description	
			Identification A (by IR)	
			Identification B by melting point	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by UV)	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
474	547	Adenosine Injection 6 mg/ 2 ml	Description	
			Identification (by HPLC)	
			Related substances (by HPLC)	
			pH	
			Extractable volume	
			Particulate matter	
			Bacterial endotoxins	
			Assay: (by HPLC)	
			Sterility	
475	548	Atorvastatin Tablets IP 40 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
476	549	Clopidogrel and Aspirin Tablets Clopidogrel 75 mg and Aspirin 75 mg	Description	
			Identification of:	
			Clopidogrel bisulphate (by HPLC)	
			Aspirin (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Clopidogrel (by HPLC)	
			Aspirin (by HPLC)	
			Identification of colour	
477	550	Fenofibrate Capsules / Tablets IP 200 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of packaged dosage forms	
			Assay: (by HPLC)	
478	551	Isoprenaline Injection IP 2 mg/ml	Description	
			Identification A (by TLC)	
			Identification B (Chemical)	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
479	552	Metoprolol Tablets IP 25 mg	Description	
			Identification (by IR)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
480	553	Metoprolol Suscinate Extended Release Tablets USP 50 mg	Description	
			Identification A (by IR)	
			Identification B (by IR)	
			Average Weight	
			Dissolution: (by HPLC)	
			After 1 hour	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			After 4 hours	
			After 8 hours	
			After 20 hours	
			Uniformity of dosage Units - Content uniformity (by HPLC)	
			Assay: (by HPLC)	
481	554	Noradrenaline Injection IP 2 mg/ml	Description	
			Identification (Chemical)	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: (by UV)	
			Sterility	
482	555	Prazosin Tablets (Extended Release) 2.5 mg	Description	
			Identification (by UV)	
			Average weight	
			Uniformity of Content (by UV)	
			Dissolution (by UV)	
			1st time point	
			2nd time point	
			3rd time point	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Identification of Colour	
483	556	Telmisartan Tablets IP 40 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
484	557	Urokinase Injection 5 Lac Unit (Lyophilized)	NQ	
485	558	Betamethasone Dipropionate Cream IP 0.05%	Description	
			Identification (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
486	559	Betamethasone Lotion IP 0.05%	Description	
			Identification (by TLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
487	560	Clindamycin Phosphate Gel USP 1%	Description	
			Identification (by HPLC)	
			Minimum fill	
			pH	
			Assay: (by HPLC)	
488	561	Clobetasol Propionate Cream 0.05%	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
489	564	Glycerin IP	Description	
			Identification B (Chemical)	
			Identification C (Chemical)	
			Identification D: Refractive index	
			Appearance of solution	
			Acidity or alkalinity	
			Heavy metals	
			Iron	
			Chlorides	
			Sulphates	
			Aldehydes and reducing substances	
			Ester	
			Ethylene glycol, diethylene glycol and related substances (by GC)	
			sugars	
			Sulphated ash	
			Water	
			Net content	
			Assay: Glycerin (Blank Titration)	
490	565	Ketoconazole Cream 2%	Description	
			Identification (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
491	568	Permethrin Lotion 5%	Description	
			Identification (by HPLC)	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
492	569	Permethrin Cream 5%	Description	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification (by HPLC)	
			Uniformity of weight: Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
493	570	Tretenoin Cream USP 0.025%	Description	
			Identification (by HPLC)	
			Minimum fill	
			Assay: (by HPLC)	
494	571	Povidone Iodine Ointment USP 5%	Description	
			Identification A	
			Identification B	
			Minimum fill	
			pH	
			Assay: (by potentiometer)	
495	572	Povidone Iodine Solution IP 10%	Description	
			Identification A	
			Identification B	
			Identification C	
			Contents of Packaged Dosage Forms	
			pH	
			Assay: Povidone iodine	
496	573	Silver Sulphadiazine Cream IP 1%	Description	
			Identification (by TLC)	
			pH of 5%w/v resulting solution	
			Contents of Packaged Dosage Forms	
			Microbial contamination	
			Escherichia coli	
			Staphylococcus species	
			Pseudomonas aeruginosa	
			Salmonella species	
			Shigella	
			Assay: (by HPLC)	
497	574	Spironolactone Tablets IP 50 mg	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Identification C (Chemical)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by UV)	
498	575	Finasteride Tablets IP 5 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
499	576	Tamsulosin HCI Tablets/Capsule 0.4 mg	Description	
			Identification A (by HPLC)	
			Identification B (by UV)	
			Average net content	
			Uniformity of content (by HPLC)	
			Related Substances (By HPLC)	
			Dissolution: (by HPLC)	
			1st time point	
			2nd time point	
			3rd time point	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity content (by HPLC)	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
500	579	Flavoxate Tablets IP 200 mg (Coated Tablets)	Description	
			Identification A (by IR)	
			Identification B (by TLC)	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Related substances (by TLC)	
			3-Methylflavone-8-carboxylic acid (by TLC)	
			Assay: (by UV)	
			Identification of colours	
501	580	Chlorhexidine Mouthwash IP 0.2%	Description	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification (by HPLC)	
			4-Chloroaniline (by GC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colours	
502	581	Dental Gel: Choline salicylate 8.7%, Benzalkonium Chloride 0.01%, Lignocaine HCl 2% (flavoured gel base)	Description	
			Identification of: Choline salicylate	
			Lignocaine hydrochloride	
			Chlorine	
			Contents of Packaged Dosage Forms	
			Assay:	
			Choline salicylate	
			Lignocaine hydrochloride	
503	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)	Description	
			Identification of:	
			For Poatassium nitrate	
			For Sodium Monofluorophosphate	
			pH	
			Contents of Packaged Dosage Forms	
			Assay:	
			For Potassium nitrate	
			For Sodium Monofluorophosphate	
			Identification of colours	
504	583	Gum Paint containg Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1%	Description	
			Identification of:	
			Tannic acid	
			Cetrimide	
			Zinc	
			chloride	
			PH	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay:	
			Tannic acid	
			Cetrimide	
			Zinc chloride	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
505	584	Metronidazole 1% and Chlorhexidine gluconate 0.25% Gel	Description	
			Identification of:	
			Metronidazole benzoate (by HPLC)	
			Chlorhexidine gluconate (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Metronidazole (by HPLC)	
			Chlorhexidine gluconate (by HPLC)	
506	585	Ciprofloxacin 0.3% and Dexamethasone 0.1% Ear Drops Ciprofloxacin and Dexamethasone Otic Suspension USP	Description	
			Identification A (by HPLC)	
			Ciprofloxacin	
			Dexamethasone	
			pH	
			Limit of Ciprofloxacin Formamide (By HPLC)	
			Related Compound (By HPLC)	
			Ciprofloxacin	
			Dexamethasone	
			Contents of Packaged Dosage Forms	
			Particle Size	
			Osmolality and Osmolarity	
			Assay: by HPLC)	
			Ciprofloxacin	
			Dexamethasone	
			Sterility	
507	586	Clotrimazole 1% with Beclomethasone Dipropionate 0.025% Ear Drops	Description	
			Identification of:	
			Clotrimazole (by HPLC)	
			Beclomethasone Dipropionate (by HPLC)	
			pH	
			Contents of Packaged Dosage Forms	
			Assay:	
			Clotrimazole (by HPLC)	
			Beclomethasone Dipropionate (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
508	588	Neomycin, Polymixin B and Hydrocortisone Ear Drops (Neomycin sulphate 3400 IU, Polymixin B Sulphate 10000 IU, and Hydrocortisone 10 mg per ml) Neomycin and Polymixin B Sulfate and Hydrocortisone Otic Solution USP	Description	
			Identification (by TLC)	
			pH	
			Net content	
			Assay:	
			Neomycin sulphate (by Microbiological assay)	
			Polymixin B Sulphate (by Microbiological assay)	
			Hydrocortisone (by HPLC)	
			Sterility	
509	589	Ceruminolytic Drops (Wax dissolving ear drops): Paradichlorobenzene 2%, Benzocaine 2.7%, Chlorbutol 5%, Turpentine oil 15%	Description	
			Identification of:	
			Benzocaine (by GC)	
			Chlorbutol (by GC)	
			Tupentine oil (by GC)	
			Paradichlorobenzene (by GC)	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay:	
			Benzocaine (by GC)	
			Chlobutol (by GC)	
			Turpentine oil (by GC)	
			Paradichlorobenzene (by GC)	
510	590	Domperidone Oral Drops 10 mg/ ml	Description	
			Identification (by HPLC)	
			weight per ml	
			pH	
			Contents of Packaged Dosage Forms	
			Identification of colour	
			Assay: (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
511	591	Drotaverine & Mefenamic Acid Tablets Drotaverine 80 mg and Mefenamic Acid 250 mg	Description	
			Identification of:	
			Mefenamic acid (by HPLC)	
			Drotaverine hydrochloride (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Drotaverine Hydrochloride (by HPLC)	
			Mefenamic acid (by HPLC)	
			Identification of colour	
512	592	Lactic Acid Bacillus Tablets 60 million spores	Description	
			Identification	
			Average weight	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by Microbiological assay)	
513	593	Lactulose solution USP/ BP 10 gm/ 15 ml or 3.35gm/5 ml	Description	
			Identification A (by HPLC)	
			Identification B	
			Unifomity Of dosage Unit	
			Organic impurities (by HPLC)	
			Fructose	
			Galactose	
			Epilactose	
			Lactose	
			Anhydrous Lactose	
			pH	
			Assay: (by HPLC with RI detector)	
			Microbial Enumeration Test and tests for specified microorganisms:	
			Total bacterial count	
			Salmonella	
			E. coli	
514	594	Liquid Paraffin IP	Description	
			Weight per ml	
			Dynamic viscosity	
			Acidity or alkalinity	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Light absorption (by UV)	
			Readily carbonisable substances	
			Solid paraffins	
			Sulphur compounds	
			Net content	
515	595	Ondansetron Orally Disintegrating Tablets IP 4 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Disintegration Time	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Uniformity of content (by HPLC)	
			Contents of packaged dosage forms	
			Assay: (by HPLC)	
516	596	Pantoprazole 40 mg and Domperidone 30 mg SR Capsules Pantopazole as enteric coated pellets, and Domperidone as sustained release pellets	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution of Pantoprazole (by HPLC)	
			At Acid stage:	
			At Buffer stage	
			Dissolution: Release pattern of Domperidone (by HPLC)	
			After 1 hour	
			After 4 hours	
			After 8 hours	
			After 12 hours	
			Related substances:	
			for Pantoprazole (by HPLC)	
			for Domperidone (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Pantoprazole (by HPLC)	
			Domperidone (by HPLC)	
			Identification of colours	
517	597	Ursodeoxycholic Acid Tablets 300 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
518	598	Allopurinol Tablets IP 100 mg	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
519	599	Hydroxychloroquine Sulphate Tablets 200 mg	Description	
			Identification A (by IR)	
			Identification B (Chemical)	
			Average weight	
			Uniformity of weight	
			Related substances (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
520	600	Leflunomide Tablets IP/USP 10 mg (Film coated)	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
521	601	Leflunomide Tablets IP/USP 20 mg (Film coated)	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
522	602	Sulfasalazine Delayed Release Tablets USP/ Gastroresistant Sulfasalazine Tablets BP 500 mg	Description	
			Identification A (byIR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity Of Weight	
			Content packaged dosage forms (weight variation)	
			Impurity (By HPLC)	
			Dissolution: (by UV)	
			1st Acid stage	
			2nd Buffer stage	
			Salicylic Acid and Sulphapyridine (By HPLC)	
			Related Substances (By HPLC)	
			Assay: (by UV)	
523	603	Gliclazide and Metformin Tablets Gliclazide 80 mg and Metformin Hydrochloride 500 mg	Description	
			Identification of:	
			Gliclazide (By HPLC)	
			Metformin hydrochloide (By UV)	
			Average weight	
			Uniformity of weight	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Gliclazide (by HPLC)	
			Metformin hydrochloride (by UV)	
524	604	Glucagon for Injection USP 1 mg	Description	
			Identification (by HPLC)	
			Glucagon Bioidentity test (HPLC)	
			Average Weight	
			pH	
			Water	
			Constituted Solution	
			Clarity of solution test a and b	
			Organic impurities (by HPLC)	
			Uniformity of doasge unit (Uniformity of weight)	
			Particulate contamination	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Bacterial endotoxins	
			Assay: HPLC	
			Sterility	
525	605	Medroxyprogesterone acetate Tablets IP 10 mg	Description	
			Identification A (by IR)	
			Dissolution (By HPLC)	
			Impurity F (6ά- methyl-3,20-dioxo-5ß-pregnan-17-yl acetate (by TLC)	
			Related Substances (by HPLC)	
			Average Weight	
			Uniformity of content (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
526	607	Thyroxine Tablets IP 50 mcg	Description	
			Identification A	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	
527	608	Octreotide Injection 50 mcg/ ml	Description	
			Identification (HPLC)	
			pH	
			Nominal Volume	
			Uniformity Of volume	
			Particulate matter	
			Extractable volume	
			Assay: (by HPLC)	
			Sterility	
528	610	Chlorzoxazone, Diclofenac Sodium & Paracetamol Tablets (Chlorzoxazone 250 mg, Diclofenac Sodium 50 mg & Paracetamol 325 mg)	Description	
			Identification of:	
			Chlorzoxazone (by HPLC)	
			Diclofenac sodium (by HPLC)	
			Paracetamol (by HPLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of Content of Diclofenac sodium (by UV) (if applicable)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Chlorzoxazone (by HPLC)	
			Diclofenac sodium (by HPLC)	
			Paracetamol (by HPLC)	
529	612	Betaxolol Eye Drops 0.5%	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			pH	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Sterility	
530	613	Carboxymethylcellulose Eye Drops 0.5%	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Identification C (Chemical)	
			pH	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
			Sterility	
531	614	Phenylephrine Hydrochloride Ophthalmic Solution USP/ Phenylephrine Eye Drops BP 5%	Description	
			Identification A (by TLC)	
			pH	
			Net content	
			Assay: (by HPLC)	
			Sterility	
532	615	Mifepristone Tablets IP 200 mg	Description	
			Identification A (by HPLC)	
			Identification B (by UV)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
533	616	Formoterol Fumerate and Budesonide Powder for Inhalation IP 6 mcg + 200 mcg	Description	
			Identification A (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Uniformity of delivered dose (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Formoterol Fumerate	
			Budesonide	
534	617	Budesonide Powder for Inhalation 200 mcg	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Average weight	
			Epimer A (by HPLC)	
			Uniformity of delivered dose (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
535	618	Ipratropium Powder for Inhalation IP 40 mcg	Description	
			Identification A (TLC)	
			Identification B (Chemical)	
			Identification C (by HPLC)	
			Average Fill	
			Uniformity of delivered dose (by HPLC)	
			Acceptance Criteria	
			No.of deliveries per container	
			deposition of emitted dose and fine particle dose	
			Related substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Microbial Contamination	
			E. coli	
			S. Aureus	
			P. Aeruginosa	
536	619	Terbutaline Tablets IP 2.5 mg	Description	
			Identification A (by UV)	
			Identification B (by TLC)	
			Average weight	
			Uniformity of content (by UV)	
			Dissolution (by UV)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
537	620	Xylometazoline Nasal Drops IP 0.1 %	Description	
			Identification A (by IR)	
			Identification B (by Chemical)	
			pH	
			N-(2-Aminoethyl)-4-Tert -butyl-2,6-Xylylacetamide (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Xylometazoline hydrochloride (by UV)	
538	621	Sodium Chloride Injection IP	Description	
			Identification (by Chemical)	
			Heavy metals	
			pH	
			Particulate contamination (by particle counter)	
			Extractable volume	
			Bacterial endotoxins	
			Assay: Sodium chloride	
			Sterility	
539	622	Calcium Carbonate & vitamin D3 Tablets / Calcium with Vitamin D Tablets USP/ Calcium and Colecalciferol Tablets BP (Elemental Calcium 500 mg, Vitamin D3- 250 IU)	Description	
			Identification A (by HPLC)	
			Identification B (Chemical)	
			Average weight	
			Dissolution for Calcium (by titration)	
			Uniformity of content: (Vitamin D3) (by HPLC)	
			Assay:	
			Calcium carbonate (by titration)	
			Vitamin D3 (by HPLC)	
540	623	Cholecalciferol granules 60, 000 IU/ gm	Description	
			Identification (by HPLC)	
			Seal test	
			Uniformity of Content (By UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
541	624	Mecobalamin Injection 500 mcg/ ml	Description	
			Identification (by Chemical)	
			pH	
			Extractable volume	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Particulate matter	
			Assay: (by Chemical)	
			Sterility	
542	626	Pyridoxine Tablets IP 10 mg	Description	
			Identification A (by UV)	
			Identification B (Chemical)	
			Average weight	
			Related substances (by TLC)	
			Uniformity of content (by UV)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
543	627	Pyridoxine Tablets IP 40 mg	Description	
			Identification A (by UV)	
			Identification B	
			Average weight	
			Related substances (by TLC)	
			Uniformity of weight	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: by UV)	
544	629	Thiamine Tablets IP 100 mg	Description	
			Identification A (by Chemical)	
			Identification B (by Chemical)	
			Identification C (by Chemical)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
545	630	Calcitriol Capsules IP 0.25 mcg	Description	
			Identification A (by HPLC)	
			Average net content	
			Uniformity of content	
			Disintegration time	
			Assay (By HPLC)	
			Contents of Packaged Dosage Forms	
546	631	Alendronate Sodium Tablets USP / BP 35 mg	Description	
			Identification (by HPLC)	
			Average weight	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Uniformity of dosage Units (weight variation)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
547	632	Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion)	Description	
			Identification of:	
			Mannitol (by TLC)	
			Glycerin	
			pH	
			Particulate contamination (by particle counter)	
			Bacterial endotoxins	
			Extractable volume	
			Assay:	
			Mannitol (by volumetric analysis)	
			Glycerin (by volumetric analysis)	
			Sterility	
548	633	Normal Human Intravenous Immunoglobulin 5 gm/100 ml	NQ	
549	634	Pregabalin Capsules IP 75 mg	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
550	635	Surfactant for intratrecheal instillation (natural bovine lung surfactant)	NQ	
551	636	Ramipril Tablets IP 2.5 mg	Description	
			Identification (by IR)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
552	638	Neostigmine Injection IP 2.5 mg/5 ml	Description	
			Identification A (by UV)	
			Identification B (by TLC)	
			Identification C (Chemical)	
			pH	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			3-Hydroxy trimethylanilinium methyl sulphate (by HPLC)	
			Extractable volume	
			Particulate matter	
			Assay: (by UV)	
			Sterility	
553	639	Oseltamivir Capsule IP 75 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 75mg	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
554	640	Oseltamivir Capsule IP 45 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 45mg	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
555	641	Oseltamivir Capsule IP 30 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 30 mg]	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
556	642	Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml. [Each ml contains 12 mg Oseltamivir base after reconstitution]	Description	
			Identification A (by HPLC)	
			Identification B (Chemical)	
			pH	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Water	
			Weight per ml	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Stability of suspension (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
557	642A	Oseltamivir Phosphate For Oral Suspension IP 12 Mg/Ml (Each Ml Contains 12 Mg Oseltamivir Base After Reconstitution)	Description	
			Identification A (by HPLC)	
			Identification B	
			Water	
			pH	
			Weight per ml	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Stability of suspension (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
558	644	Vitamin K1 (Phytomenadione) Injection 1 mg/0.5 ml Ampoule (aqueous Preparation) Each Pack contains:(i) One 0.5 ml Ampoule of Vitamin K 1(ii) One 1 ml disposable syringe with one 26 gaze needle	Description	
			Identification A (by UV)	
			Identification B (by UV)	
			pH	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
559	645	ACT Containing 3 Tablets of Artesunate (each Tablets of artesunate 25mg strength) and 1 Tablets of Sulphadoxine Pyremethamine (250mg+12.5mg)	**Artesunate tablets**	
			Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Pyrimethamine and sulphadoxine tablets IP	
			Description	
			Identification (by TLC)	
			Average weight	
			Uniformity of Content Pyrimethamine by HPLC (if Applicable)	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Pyrimethamine (by HPLC)	
			Sulphadoxine (by HPLC)	
560	646	ACT Containing 3 Tablets of Artesunate (50mg each) and 1 Tablets of Sulphadoxine Pyremethamine (500+25)mg	**Artesunate tablets**	
			Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Pyrimethamine and sulphadoxine tablets IP	
			Description	
			Identification (by TLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of Content Pyrimethamine by HPLC (if Applicable)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Pyrimethamine (by HPLC)	
			Sulphadoxine (by HPLC)	
561	647	ACT Containing 3 Tablets of Artesunate (100mg each) and 1 Tablets of Sulphadoxine Pyremethamine (750+37.5)mg	**Artesunate tablets**	
			Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Pyrimethamine and sulphadoxine tablets IP	
			Description	
			Identification (by TLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of Content Pyrimethamine by HPLC (if Applicable)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Pyrimethamine (by HPLC)	
			Sulphadoxine (by HPLC)	
562	648	ACT Containing 3 Tablets of Artesunate 150mg and 2 Tablets of Sulphadoxine and Pyremethamine (500mg+25mg)	**Artesunate tablets**	
			Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Pyrimethamine and sulphadoxine tablets IP	
			Description	
			Identification (by TLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Uniformity of weight	
			Uniformity of Content Pyrimethamine by HPLC (if Applicable)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Pyrimethamine (by HPLC)	
			Sulphadoxine (by HPLC)	
563	649	ACT Containing 3 Tablets of Artesunate (each 200 mg) and 2 Tablets of Sulphadoxine Pyremethamine (750+37.5mg) each or 3 Tablets Sulphadoxine Pyremethamine (500+25mg) each	**Artesunate tablets**	
			Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Pyrimethamine and sulphadoxine tablets IP	
			Description	
			Identification (by TLC)	
			Average weight	
			Uniformity of weight	
			Uniformity of Content Pyrimethamine by HPLC (if Applicable)	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Pyrimethamine (by HPLC)	
			Sulphadoxine (by HPLC)	
564	650	Glyceryl Trinitrate Tablets 2.6 mg Controlled Release tablets	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			Dissolution by HPLC	
			After 1st hour	
			After 2nd hour	
			After 4th hour	
			After 6th hour	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
565	651	Artemether and Leumefantrin Tablets (80 mg + 480 mg)	Description	
			Identification of:	
			Artemether (by HPLC)	
			Lumefantrine (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Lumefantrine (by HPLC)	
			Artemether (by HPLC)	
566	652	Methylcobalmine 500 mcg Tablets	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	
			Identification of colour	
567	653	Methylcobalmine 1500 mcg Tablets	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	
			Identification of colour	
568	654	Atropine Sulphate Injection IP 0.6 mg/ml (SC/IM/IV use)	Description	
			Identification A (by TLC)	
			Identification B (by HPLC)	
			pH	
			Bacterial endotoxins	
			Extractable volume	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
569	655	Fentanyl Citrate Injection IP 50 mcg/ml	Description	
			Identification A (by UV)	
			Identification B (by HPLC)	
			Identification C (Chemical)	
			Related Substances (By HPLC)	
			Bacterial endotoxins	
			Particulate matter	
			Assay: (by HPLC)	
			Sterility	
570	656	Naproxen Tablets IP 500 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Average weight	
			Dissolution (by UV)	
			Uniformity of weight	
			Related Substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
571	657	Naproxen Tablets IP 250 mg	Description	
			Identification A (by IR)	
			Identification B (by UV)	
			Average weight	
			Dissolution (by UV)	
			Uniformity of weight	
			Related Substances (by TLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by UV)	
572	658	Etoricoxib Tablets IP 90 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by UV)	
			Uniformity of weight	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour	
573	659	Levocetrizine Tablets 5 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Dissolution (by HPLC)	
			Uniformity of content (by HPLC)	
			Related substances (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Content of package dosage form	
			Assay: (by HPLC)	
574	660	Montelukast (10 mg) +Levocetrizine (5mg) Tablets	Description	
			Identification (HPLC)	
			Average weight	
			Dissolution of:	
			Montelukast (by HPLC)	
			Levocetrazine (by HPLC)	
			Related substances (by HPLC)	
			Content uniformity of: Montelukast (by HPLC)	
			Levocetrazine (by HPLC)	
			Assay:	
			Montelukast (by HPLC)	
			Levocetrazine (by HPLC)	
575	661	Sodium Valproate Tablets (Gastro Resistant) IP 500 mg	Description	
			Identification A (by IR)	
			Average weight	
			Related substances (by GC)	
			Uniformity of Weight	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay: (by GC)	
			Identification of colour	
576	662	Clobazam Tablets/Capsule 5 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
577	663	Clobazam Tablets/Capsule 10 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Assay: (by HPLC)	
578	664	Levetiracetam 500 mg Tablets	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity Of Weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
579	665	Levetiracetam 100 mg/ml oral solution	Description	
			Identification (by HPLC)	
			pH	
			Relates substances (by HPLC)	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Identification of colour (by TLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
580	666	Levetiracetam Injection 500 mg/5ml	Description	
			Identification (by HPLC)	
			Organic Impurity (by HPLC)	
			pH	
			Bacterial endotoxins	
			Volume in Container	
			Particulate matter (by Liquid particle analyser)	
			Assay: (by HPLC)	
			Sterility	
581	667	Gabapentin Tablets 100 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
582	668	Gabapentin Cap 300 mg	Description	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
583	669	Co-trimoxazole Tablet (Trimethoprim 160mg+Sulphamethoxazole 800mg)	Description	
			Identification A (by IR)	
			Identification B (by IR)	
			Identification C (by TLC)	
			Average weight	
			Contents of Packaged Dosage Forms	
			Uniformity of weight	
			Disintegration Time	
			Assay:	
			Trimethoprim (by HPLC)	
			Sulphamethoxazole (by HPLC)	
584	670	Coal tar 6% & Salicylic Acid 3% Ointment	Description	
			Identification of Coal Tar	
			Identification of Salicyclic acid (by UV)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Salicyclic acid (by UV)	
585	671	Calamine Lotion IP	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Weight per ml	
			Contents of Packaged Dosage Forms	
			Assay: Zinc oxide	
			Additional test: Content of	
			Glycerin 5%v/v	
			Sodium citrate 0.5%w/v	
			Microbial Contamination	
			Staphylococcus aureus	
			Pseudomonas aeruginosa	
586	672	Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 350 mg Iodine/ml.	Description	
			Identification (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Organic impurities (by HPLC)	
			Bacterial endotixins	
			pH	
			Particulate matter (by Liquid particle size analyzer)	
			Free Iodide	
			Sterility	
			Extractable volume	
			Assay	
587	673	Diagnostic Stick for Multiple use strip (sugar, ketone, Albumin)	NQ	
588	673A	Diagnostic strip for Glucose, Ketone	NQ	
589	673B	Diagnostic strip for Glucose, Protein	NQ	
590	674	Quetiapine Tablets IP 50 mg	Description	
			Identification A (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
591	675	Quetiapine Tablets IP 25 mg	Description	
			Identification A (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by UV)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
592	676	Vitamin D3 Oral Solution 60000 IU	Description	
			Identification	
			Weight per ml	
			Acid value	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Microbial Examination	
			Total aerobic count	
			Total fungal count	
			E. coli	
593	677	Cyclosporine Capsules USP 50 mg	Description	
			Identification (by HPLC)	
			Average net content	
			Uniformity of weight	
			Dissolution (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Water	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
594	678	Clonazepam Tablets IP 0.5 mg	Description	
			Identification A (by IR)	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Dissolution (by HPLC)	
			Related substances (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
595	679	Aspirin Tablets IP (Gastro-resistant) 150 mg	Description	
			Identification (Chemical)	
			Average weight	
			Dissolution A (by UV) Acid stage	
			Dissolution B (by UV) Buffer stage	
			Uniformity of weight	
			Salicylic acid (by HPLC)	
			Assay: (by HPLC)	
			Identification of colours (by TLC)	
596	680	Insulin Glargine 100 IU/ml	NIB	
597	681	Insulin Glargine 100 IU/ml	NIB	
598	682	Teneligliptin Tablets 20 mg	Description	
			Identification of Teneligliptin (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
599	683	Injection Aztreonam 1 gm	Description	
			Identification (HPLC)	
			pH	
			Bacterial endotoxins	
			Particulate matter	
			Extractable volume	
			Assay: by HPLC	
			Sterility	
600	684	Framycetin Sulphate Cream 1%	Description	
			Identification	
			Framycetin Sulphate	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Methyl Paraben (By HPLC)	
			Propyl Paraben (By HPLC)	
			Microscopic Examination	
			Check for Particulate matter	
			Contents of Packaged Dosage Forms	
			Assay:	
			Framycetin Sulphate (Microbial Assay)	
			Methyl Paraben (By HPLC)	
			Propyl Paraben (By HPLC)	
601	685	Framycetin Sulphate Cream 1%	Description	
			Identification	
			Framycetin Sulphate	
			Methyl Paraben (By HPLC)	
			Propyl Paraben (By HPLC)	
			Microscopic Examination	
			Check for Particulate matter	
			Contents of Packaged Dosage Forms	
			Assay:	
			Framycetin Sulphate (Microbial Assay)	
			Methyl Paraben (By HPLC)	
			Propyl Paraben (By HPLC)	
602	686	Artemether and Leumefantrin Tablets (40 mg + 240 mg)	Description	
			Identification of:	
			artemether (by HPLC)	
			lumefantrine (by HPLC)	
			Average weight	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Lumefantrine (by HPLC)	
			Artemether (by HPLC)	
603	687	Concentrated Solution for Haemodialysis B.P Sodium Hydrogen carbonate concentrate in 10 Litre Cans.	Description	
			Identification for	
			Potassium	
			Calcium	
			Sodium	
			Chlorides	
			Lactates	
			Carbonates and hydrogen carbonates	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Magnesium	
			Glucose	
			Tests for	
			Appearance of solution	
			Aluminium	
			Extractable volume	
			Microbial contamination: TAMC.	
			Bacterial endotoxins	
			Assay for:	
			Sodium by AAS & AES	
			Potassium by AAS	
			Calcium by AAS	
			Magnesium by AAS	
			Total chloride by titration	
			Acetate by potentiometric titration	
			Lactate by potentiometric titration	
			Sodium hydrogen carbonate by potentiometric titration	
			Reducing sugars by titration	
604	688	Dried Human Anti haemophlic Fraction IP (Dried Factor VIII Fraction IP) 500 IU/ Vial (IV use)	NQ	
605	689	Dried Human Anti haemophlic Fraction IP (Dried Factor VIII Fraction IP) 1000 IU/ Vial (IV use)	NQ	
606	690	Recombinant Coagulation Factor VIIa 1 mg	NQ	
607	691	Recombinant Coagulation Factor VIIa 2 mg	NQ	
608	692	Cough Syrup/Expectorant Each 5ml contains Ambroxol 15mg, Terbutaline Sulphate IP 1.5mg, Guaphenesin IP 50mg, Menthol IP 1mg.	Description	
			Identification of:	
			Ambroxol Salt	
			Guaphenesin	
			Terbutaline	
			Menthol	
			pH	
			Contents of Packaged Dosage Forms	
			Identification of colour	
			Assay:	
			Ambroxol (by HPLC)	
			Guaphenesin (by Chemical)	
			Terbutaline (blank titration)	
			Menthol (by UV)	
			Microbiological Examination	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Total Aerobic count	
			Total Fungal count	
			E. coli	
609	448W	Iron And Folic Acid Syrup IP	Description	
			Identification A (Chemical)	
			Identification B (Chemical)	
			Identification C (by HPLC)	
			Weight per ml	
			pH	
			Contents of Packaged Dosage Forms	
			Microbial Contamination	
			Total aerobic viable count	
			E. coli	
			Assay: Folic acid 0.5 mg (by HPLC)	
			Ferrous sulphate calculated as elemental iron	
			Identification of colour (by TLC)	
610	489P	Iron And Folic Acid Tablets	Description	
			Identification of:	
			Folic acid (by HPLC)	
			Ferrous sulphate (Chemical)	
			Average weight	
			Uniformity of weight	
			Ferric iron	
			Uniformity of content: Folic acid (by HPLC)	
			Disintegration Time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Folic acid (by HPLC)	
			Dried ferrous sulphate calculated as elemental iron	
			Identification of colour	
611	490W	Iron And Folic Acid Tablets (Wifs Junior)	Description	
			Identification of:	
			Folic acid (by HPLC)	
			Ferrous sulphate	
			Average weight	
			Uniformity of weight	
			Ferric iron	
			Uniformity of content: Folic acid (by HPLC)	
			Disintegration Time	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Contents of Packaged Dosage Forms	
			Assay:	
			Folic acid (by HPLC)	
			Dried ferrous sulphate calculated as elemental iron	
			Identification of colour	
612	NE1	Buprenorphine 2mg + Naloxone 0.5 mg Tablets	Description	
			Identification of:	
			Buprenorphine (by HPLC)	
			Naloxone (by HPLC)	
			Average weight	
			Disintegration time	
			Content uniformity of: Buprenorphine (by HPLC)	
			Naloxone (by HPLC)	
			Contents of Packaged Dosage Forms	
			Assay:	
			Buprenorphine (by HPLC)	
			Naloxone (by HPLC)	
613	NE2	Misoprostol Tablets 200 mcg	Description	
			Identification A (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	
614	NE3	Treponemal-Specific Rapid (Point-of-Care) Diagnostic Test for Syphilis	NQ	
615	NE4	Whole Blood Finger Prick Test kit for HIV (Rapid)	NQ	
616	NE6	Multiple Urine Analysis Strip	NQ	
617	NE7	Injection rTPA (Recombinant tissue Plasminogen Activator) for stroke management 20 mg	NQ	
618	NE8	Injection rTPA (Recombinant tissue Plasminogen Activator) for stroke management 50 mg	NQ	
619	NE9	Levothyroxine Sodium Tablets IP 25 mcg	Description	
			Identification A	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
620	NE10	Levothyroxine Sodium Tablets 50 mcg	Description	
			Identification A	
			Identification B (by HPLC)	
			Average weight	
			Uniformity of content (by HPLC)	
			Contents of Packaged Dosage Forms	
			Disintegration time	
			Assay: (by HPLC)	
621	NE11	Post exposure prophylaxis drugs for HIV- Drug Combination : Tenofivir 300 mg+ Lamivudine 300 mg + Efavirenz 600 mg	Description	
			Identification (by HPLC)	
			Average weight	
			Uniformity of weight	
			Dissolution of: (by HPLC)	
			Tenofivir	
			Lamivudine	
			Efavirenz	
			Contents of Packaged Dosage Forms	
			Assay: (by HPLC)	
			Tenofivir	
			Lamivudine	
			Efavirenz	
622	NE12	Anti - Oxidants Capsules (Beta Carotene – 10 mg, Vit - E 25mg, Vit - C 100 mg, Copper 1.5 mg, Manganese 1.5 mg, Zinc 7.5 mg, Selenium 150 microgram	Description	
			Identification	
			Beta Carotene (by UV)	
			Vitamin E (by UV)	
			Vitamin C (by Chemical)	
			Copper (by ICP MS)	
			Manganese (by ICP MS)	
			Zinc (by ICP MS)	
			Selenium (by ICP MS)	
			Average Fill	
			Uniformity of weight	
			Disintegration time	
			Contents of Packaged Dosage Forms	
			Assay:	
			Beta Carotene (by UV)	
			Vitamin E (by UV)	

S. No. (1)	Code No. (2)	Name of item with specification (3)	Test parameters to be carried out (4)	Test parameters proposed to be carried out by bidder (5)
			Vitamin C (byChemical)	
			Copper (by ICP MS)	
			Manganese (by ICP MS)	
			Zinc (by ICP MS)	
			Selenium (by ICP MS)	

ANNEXURE –VIII
Ref: Clause no. 3 (p)

To fill up the remark column of the enclosed Performa to access the existing facilities of your laboratories

A - General requirements and premises

S.N.	Details of the requirement	Remark
1	For Laboratory management a qualified individual known as quality manager or technical manager is appointment.	
2	The Laboratory is designed, contracted and maintained to prevent entry of insects and rodents besides cross contaminations ;	
3	Interior surface (wall, floor, and ceilings) are smooth and free from cracks, and permit easy cleaning and disinfection ;	
4	Adequate provision for space and equipment for carrying out necessary test is provided & also unities like water, power and gas ;	
5	Air ventilations system is provide to ensure dust free environments	
6	The laboratories provided with adequate lighting and ventilation, air conditioning to maintain satisfactory temperature and relative humidity	
7	The faculties of drainage system and to prevent water logging in the laboratory	
8	Tables tops is made of with acid, alkali and solvent resistant material	
9	Adequate space with proper storage conditions in the laboratory shall be provided for keeping Reference and working standards	
10	The air circulation is maintained in the area where sterility test is carried out as per Schedule M.	

B- Personal & Equipment

S.N.	Details of the requirement	Remark
1	Staff in the laboratory shall possess necessary qualification, proper training and shall have Adequate, experience for the assigned duties.	
2	A training record of all the personal shall be maintained.	
3	Head of the laboratory must be high professional standing with experience in drug analysis and laboratories management	
4	The analytical instrument shall be housed in the dust-free environment and with controlled conditions of temperature and humidity	
5	A progress register for non functional equipments and action for procurement of spares and accessories, monitoring there of, shall be maintained	
6	A standard operating procedure for preventive maintenance of machine or equipment or apparatus shall be prepared by the laboratory	
7	Equipments such as burette, pipettes, volumetric flasks, weight boxes, thermometers etc. shall be thoroughly checked for accuracy for calibration before acceptance of use	
8	Equipments, instruments giving anomalous results or defective must be labeled as out of order	
9	Autoclaves must meet the requirements described for operations, safety and validation procedures	
10	Work involving the evolution of harmful and obnoxious vapors shall be carried out in a fume cupboard	

Chemicals and Reagents, Good housekeeping and safety

S.N.	Details of the requirement	Remark
1	All reagents and solutions in the laboratory shall be property identified with a label.	
2	A standardization register shall be maintained, with its raw date and SOP for preparation and standardization on stock solutions, standard solutions and volumetric solutions.	
3	Containers of stock solutions and of standard solutions shall bear the details.	
4	The storage and handling of chemicals and reagents shall be done in a manner considering the physicochemical properties substances and the hazard involved in their use.	
5	General and specific written down instructions for safety shall be circulated to each staff member.	
6	SOP for safety, house-keeping and loss prevention.	
7	Drinking, eating and smoking shall not be permitted in the laboratories.	
8	Staff must wear laboratory coats or other protective clothing including gloves and face masks and eye protection wherever required	
9	The laboratories shall have adequate firs aid kit and fire fighting equipments.	
10	Operators carrying out sterility tests shall wear sterilized garments including headgear, face masks and shoes.	
11	The staff must be educated in the first aid techniques, emergency care and use of antidotes.	
12	Safety rules in handling cylinders of compressed gases must be observed and staff must be familiar with relevant colors identification codes ;	
13	Protective Precautions - 1- water showered 2- Rubber suction bulbs must be used on manual and siphons ; 3- Warnings, precautions and written Instructions violent, uncontrollable or reactions. 4- Appropriate facilities for the collection, storage and disposal of wasters. 5- Safe disposal of corrosive or dangerous products by neutralization or deactivation. 6- Safety precautions to be adopted while handling potassium cyanide and bromide ; 7- SOP for handing, collection, disposal of chemical and biological wastes.	

Maintenance, calibration, and validation of equipment & Reference materials : Microbiological Cultures :

S.N.	Details of the requirement	Remark
1	All equipments, instruments and other devices used in the laboratory shall use appropriate methods and procedures for all tests or calibrations and they shall be regularly Calibrated and validated.	
2	For most of the equipments and instruments, SOP for calibration and calibration schedule be the laboratory and a logbook shall also be prepared by each laboratory for proper documentation of calibrations results.	

3	Reference material shall be traceable to agency authorized by Government of India or any other International body.	
4	The laboratory shall prepare working standard by comparing with the reference standards and shall be routinely checked for their purity.	
5	Whenever, any new reference material is received by the laboratory following details are to be written - a- Source of supply ; b- Code number of the reference material ; c- Date of receipt ; d- Batch number or identification number of the supplying agency ; e- Details like assay value, water content or information provided ; f- Storage condition of the material ; g- Date of expiry, if any and date of manufacturing if possible.	
6	SOP for maintenance of microbial culture and sub-culture must be prepared by the laboratories ;	

Quality system : & internal quality audits, management review :

S.N.	Details of the requirement	Remark
1	The measurements and calibrations shall fully conform to the compendia requirements and the method demonstrably based on validation protocols are followed.	
2	Remedial action o the observations by internal and external audits are taken appropriately	
3	Documented quality policy for the organization.	
4	Internal audits are done to assure the integrity of the analysis ad such audits shall be conducted periodically	
5	Each activity is audited at least once in a year.	
6	The quality manager shall maintain all the records of the analysis being conducted which includes test system, the type of analysis , date on which analysis is done	
7	Review yearly 1- Report or input 2- Matter arising from previous reviews ; 3- Report of external audits, if any ; 4- Surveillance report, if any ; 5- Result of proficiency testing ; 6- Complaints or feedback received from users 7- Details of in-house quality control checks ; 8- Need of amendment of the quality system and documentation ; 9- Introduction training of new staff.	

Standard operating Procedures

S.N.	Details of the requirement	Remark
1	Shall be written in a chronological order listing different steps leading to an analysis of drugs or calibration of an instruments ;	
2	Shall have SOP manuals and have periodic Review.	
3	Standard Operation Procedures for the followings are required (i) Sample handling and accountability ; (ii) Receipt identification, storage, mixing and method sampling of the test	

S.N.	Details of the requirement	Remark
	and control articles ; (iii) Record keeping, reporting, storage and retrieval of data ; (iv) Coding of different studies, handling of data including use of computerized data system : (v) Operation of technical audit personnel in performing and reporting audits, inspections and final report reviews ; (vi) Routing inspection of cleaning maintenance, testing, calibration and standardization of instruments ; (vii) Action to be taken in respect of equipment failure ; (viii) Analytical data methods (ix) Health and safety protection ; (x) Date handling and storage retrieval ; (xi) Health and safety protection ; (xii) Animal room preparations ; (xiii) Animal care ; (xiv) Storage and maintenance of microbial cultures ; (xv) Maintenance of sterility room (i.e. constant maintenance and monitoring of Aseptic condition room) ; (xvi) Use and storage of reference standards ; (xvii) Procurement of stores and equipment ; (xviii) Monitoring of testing of samples ; (xix) Method of retention of unexpended samples, their location, maintenance and disposal ; (xx) Document control ; (xxi) Redressal of technical complaints ; (xxii) House- keeping (xxiii) Corrective and preventive action ; (xxv) Calibration manual. (xxvi) Training manual.	
4	Protocols and specification archive :- List of all the pharmacopeias a file on patent and proprietary medicines (non-Pharmacopeia) test methods to specification prepared and validated by the manufacturer. The test methods shall be submitted to the concerned Drug Control Authority.	
5	Raw data - Date integrity and security shall be maintained Original entry must be saved and the system shall trail for all data.	
6	Storage and archival ; The residual sample shall be retained in proper storage condition for a period of one year after the final report.	
7	The laboratory must establish and maintain procedures for the identification collection, indexing, retrieval, storage, maintenance, and Disposal of all quality documents.	
8	All the raw date, documentation, SOP, protocols and final reports are the be retained and there shall be archives of orderly storage and expeditious retrieval of all raw data, documentation, protocols, interim and final report.	
9	The condition under which the original documents are stored must ensure	

S.N.	Details of the requirement	Remark
	their security and confidentiality.	
10	Raw data on thermal paper might fad away with time ; therefore, a photocopy of the thermal paper shall be retained in the archive.	

Above mentioned information correct as per our record and if found incorrect, RMSC may take action against our firm and reject our bid.

Signature:
Name of the Lab:
Date:
Official Seal: